<?xml version="1.0"  ?><!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd"><pmc-articleset><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" article-type="review-article" xml:lang="en" dtd-version="1.4"><processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats"><restricted-by>pmc</restricted-by></processing-meta><front><journal-meta><journal-id journal-id-type="nlm-ta">Inflammopharmacology</journal-id><journal-id journal-id-type="iso-abbrev">Inflammopharmacology</journal-id><journal-id journal-id-type="pmc-domain-id">3814</journal-id><journal-id journal-id-type="pmc-domain">phenaturepg</journal-id><journal-title-group><journal-title>Inflammopharmacology</journal-title></journal-title-group><issn pub-type="ppub">0925-4692</issn><issn pub-type="epub">1568-5608</issn><custom-meta-group><custom-meta><meta-name>pmc-is-collection-domain</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-collection-title</meta-name><meta-value>Springer Nature - PMC COVID-19 Collection</meta-value></custom-meta></custom-meta-group></journal-meta><article-meta><article-id pub-id-type="pmcid">PMC8324454</article-id><article-id pub-id-type="pmcid-ver">PMC8324454.1</article-id><article-id pub-id-type="pmcaid">8324454</article-id><article-id pub-id-type="pmcaiid">8324454</article-id><article-id pub-id-type="pmid">34331179</article-id><article-id pub-id-type="doi">10.1007/s10787-021-00850-7</article-id><article-id pub-id-type="publisher-id">850</article-id><article-version article-version-type="pmc-version">1</article-version><article-categories><subj-group subj-group-type="heading"><subject>Review</subject></subj-group></article-categories><title-group><article-title>Recent updates on immunological, pharmacological, and alternative approaches to combat COVID-19
</article-title></title-group><contrib-group><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid" authenticated="false">http://orcid.org/0000-0002-2478-7800</contrib-id><name name-style="western"><surname>Saleem</surname><given-names initials="A">Ammara</given-names></name><address><email>amarafurqan786@hotmail.com</email></address><xref ref-type="aff" rid="Aff1">1</xref></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid" authenticated="false">http://orcid.org/0000-0003-2270-6242</contrib-id><name name-style="western"><surname>Akhtar</surname><given-names initials="MF">Muhammad Furqan</given-names></name><address><email>furqan.pharmacist@gmail.com</email></address><xref ref-type="aff" rid="Aff2">2</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Haris</surname><given-names initials="M">Muhammad</given-names></name><xref ref-type="aff" rid="Aff1">1</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Abdel-Daim</surname><given-names initials="MM">Mohamed M.</given-names></name><xref ref-type="aff" rid="Aff3">3</xref><xref ref-type="aff" rid="Aff4">4</xref></contrib><aff id="Aff1"><label>1</label><institution-wrap><institution-id institution-id-type="GRID">grid.411786.d</institution-id><institution-id institution-id-type="ISNI">0000 0004 0637 891X</institution-id><institution>Department of Pharmacology, Faculty of Pharmaceutical Sciences, </institution><institution>Government College University Faisalabad, </institution></institution-wrap>Faisalabad, Pakistan </aff><aff id="Aff2"><label>2</label><institution-wrap><institution-id institution-id-type="GRID">grid.414839.3</institution-id><institution-id institution-id-type="ISNI">0000 0001 1703 6673</institution-id><institution>Riphah Institute of Pharmaceutical Sciences, Riphah International University, </institution></institution-wrap>Lahore Campus, Lahore, Pakistan </aff><aff id="Aff3"><label>3</label><institution-wrap><institution-id institution-id-type="GRID">grid.33003.33</institution-id><institution-id institution-id-type="ISNI">0000 0000 9889 5690</institution-id><institution>Pharmacology Department, Faculty of Veterinary Medicine, </institution><institution>Suez Canal University, </institution></institution-wrap>Ismailia, 41522 Egypt </aff><aff id="Aff4"><label>4</label>Department of Pharmaceutical Sciences, Pharmacy Program, Batterjee Medical College, P.O. Box 6231, Jeddah, 21442 Saudi Arabia </aff></contrib-group><pub-date pub-type="epub"><day>30</day><month>7</month><year>2021</year></pub-date><pub-date pub-type="ppub"><year>2021</year></pub-date><volume>29</volume><issue>5</issue><issue-id pub-id-type="pmc-issue-id">386880</issue-id><fpage>1331</fpage><lpage>1346</lpage><history><date date-type="received"><day>22</day><month>5</month><year>2021</year></date><date date-type="accepted"><day>29</day><month>6</month><year>2021</year></date></history><pub-history><event event-type="pmc-release"><date><day>31</day><month>07</month><year>2021</year></date></event><event event-type="pmc-live"><date><day>02</day><month>08</month><year>2021</year></date></event><event event-type="pmc-last-change"><date iso-8601-date="2024-09-27 06:25:18.853"><day>27</day><month>09</month><year>2024</year></date></event></pub-history><permissions><copyright-statement>&#169; The Author(s), under exclusive licence to Springer Nature Switzerland AG 2021</copyright-statement><license><license-p>This article is made available via the PMC Open Access Subset for unrestricted research re-use and secondary analysis in any form or by any means with acknowledgement of the original source. These permissions are granted for the duration of the World Health Organization (WHO) declaration of COVID-19 as a global pandemic.</license-p></license></permissions><self-uri xmlns:xlink="http://www.w3.org/1999/xlink" content-type="pmc-pdf" xlink:href="10787_2021_Article_850.pdf"/><abstract id="Abs1"><p id="Par1">The pandemic coronavirus disease 2019 (COVID-19) is instigated by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) that is mainly transmitted via the inhalation route and characterized by fever, coughing and shortness of breath. COVID-19 affects all age groups with no single cure. The drug discovery, manufacturing, and safety studies require extensive time and sources and, therefore, struggled to match the exponential spread of COVID-19. Yet, various repurposed drugs (antivirals, immune-modulators, nucleotide analogues), and convalescent plasma therapy have been authorized for emergency use against COVID-19 by Food and Drug Administration under certain limits and conditions. The discovery of vaccine is the biggest milestone achieved during the current pandemic era. About nine vaccines were developed for human use with varying claims of efficacy. The rapid emergence of mutations in SARS-CoV-2, suspected adverse drug reactions of current therapies in special population groups and limited availability of drugs in developing countries necessitate the development of more efficacious, safe and cheap drugs/vaccines for treatment and prevention of COVID-19. Keeping in view these limitations, the current review provides an update on the efficacy and safety of the repurposed, and natural drugs to treat COVID-19 as well as the vaccines used for its prophylaxis.</p></abstract><kwd-group xml:lang="en"><title>Keywords</title><kwd>COVID-19</kwd><kwd>Corona virus</kwd><kwd>Vaccine</kwd><kwd>Antiviral</kwd><kwd>Convalescent plasma therapy</kwd></kwd-group><custom-meta-group><custom-meta><meta-name>pmc-status-qastatus</meta-name><meta-value>0</meta-value></custom-meta><custom-meta><meta-name>pmc-status-live</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-status-embargo</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-status-released</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-open-access</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-olf</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-manuscript</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-legally-suppressed</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-pdf</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-supplement</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-pdf-only</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-suppress-copyright</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-real-version</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-scanned-article</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-preprint</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-in-epmc</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>issue-copyright-statement</meta-name><meta-value>&#169; Springer Nature Switzerland AG 2021</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec id="Sec1"><title>Introduction</title><p id="Par2">The novel coronavirus disease (COVID-19) is instigated by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (Yuan et al. <xref ref-type="bibr" rid="CR128">2020</xref>). In November 2019, Wuhan became the emerging key zone of a novel coronavirus outbreak that was characterized by upper and lower respiratory tract distress and proceeded to deleterious systemic manifestation and premature mortality. It is notorious for its exponential rise in the number of infected individuals of any age. This coronavirus was isolated and labelled as the novel virus corona disease 2019 (nCOV-2019) by Chinese scientists followed by its genome sequencing in January 2020. It caused deaths of more than 1800 while infected more than 70,000 individuals within the first 5 days of this COVID-19 that was latterly stated as a global pandemic by the World Health Organization (WHO) (Lu et al. <xref ref-type="bibr" rid="CR71">2020</xref>; Lai et al. <xref ref-type="bibr" rid="CR61">2020</xref>). To date, about 162 million people are infected and 33 million people have died owing to this malicious infection. It is mainly transmitted via inhalation route due to sneezing droplet of infective patient (Jiang et al. <xref ref-type="bibr" rid="CR49">2021</xref>).</p><p id="Par3">Novel coronavirus (family: coronaviridae; genera; &#946;-coronavirus) is a greatly varied, enclosed, and single-stranded positive-sense RNA virus that has nucleocapsid with helical symmetry (Khan et al. <xref ref-type="bibr" rid="CR56">2020</xref>). Coronavirus has spikes like a crown on its outermost surface, tiny in size (dia: 65&#8211;125&#160;nm), and 26&#8211;32 kbs length of single-stranded RNA (Shereen et al. <xref ref-type="bibr" rid="CR100">2020</xref>; Jiang et al. <xref ref-type="bibr" rid="CR49">2021</xref>).</p><p id="Par4">The positive patient expresses either symptom, that of various severity or is symptomless depending on different factors as immunity and a variant of COVID-19. The most prevailing symptoms include fever, coughing, shortness of breath, diarrhea, and vomiting. The clinical evaluation of most patients has shown a normal or low level of WBCs and lymphocytopenia. But in serious conditions, C-reactive protein, neutrophil count, blood urea, <sc>d</sc>-dimer and creatinine levels are profoundly raised. Additionally, upregulation of inflammatory mediators, i.e. interleukin (IL)-6, and tumor necrosis factor-&#945; contribute to the immune-compromised status of the patients (Quer et al. <xref ref-type="bibr" rid="CR87">2021</xref>). People with underlying diseases such as chronic obstructive pulmonary disease, diabetes, cardiovascular disease and elderly are highly prone to develop respiratory distress syndrome, coagulation, and septic shock that are hard to correct even leading to the death (Wu et al. <xref ref-type="bibr" rid="CR122">2021</xref>).</p><sec id="Sec2"><title>Pathogenesis of COVID-19</title><p id="Par5">The association of S protein with host cell surface receptors initiates virus infection. The cellular serine proteases TMPRSS2 will cleave the S protein into S1 and S2 (Walls et al. <xref ref-type="bibr" rid="CR115">2020</xref>). The C-terminal domain (CTD) of S1 particularly attaches to the receptor of host cell angiotensin-converting enzyme 2 (ACE2) and induces the conformational change of S2 that instigates the release of virus&#8217;s genome into the cytoplasm (Wang et al. <xref ref-type="bibr" rid="CR116">2020c</xref>). The viral RNA prompts replication and transcription, latterly, newly ensemble viruses are discharged out extracellularly via exocytosis (Fehr et al. <xref ref-type="bibr" rid="CR29">2015</xref>; Ray and Maunsell <xref ref-type="bibr" rid="CR89">2011</xref>). The target receptor sites for COVID-19 infection in host body are presented in Table <xref rid="Tab1" ref-type="table">1</xref><table-wrap id="Tab1" position="float" orientation="portrait"><label>Table 1</label><caption><p>Mechanism of target receptors sites and their actions in Covid-19 virus in host</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" colspan="1" rowspan="1">Target receptor</th><th align="left" colspan="1" rowspan="1">Activity</th><th align="left" colspan="1" rowspan="1">Target human cells</th><th align="left" colspan="1" rowspan="1">References</th></tr></thead><tbody><tr><td align="left" colspan="1" rowspan="1">Aminopeptidase N (APN)</td><td align="left" colspan="1" rowspan="1">Aids S protein mediated entry of virus into host cells</td><td align="left" colspan="1" rowspan="1">URT</td><td align="left" colspan="1" rowspan="1">(Li et al. <xref ref-type="bibr" rid="CR65">2018</xref>; Wong et al. <xref ref-type="bibr" rid="CR121">2017</xref>)</td></tr><tr><td align="left" colspan="1" rowspan="1">Angiotensin converting enzyme 2 (ACE2)</td><td align="left" colspan="1" rowspan="1">Aids entry of coronavirus into host, replication and normal function of ACE2 is blocked</td><td align="left" colspan="1" rowspan="1">URT</td><td align="left" colspan="1" rowspan="1">(Jia et al. <xref ref-type="bibr" rid="CR47">2005</xref>; Wong et al. <xref ref-type="bibr" rid="CR121">2017</xref>)</td></tr><tr><td align="left" colspan="1" rowspan="1">O-acetylated sialic acid</td><td align="left" colspan="1" rowspan="1">Aids entry into the cell through S1 protein</td><td align="left" colspan="1" rowspan="1">URT</td><td align="left" colspan="1" rowspan="1">(Hulswit et al. <xref ref-type="bibr" rid="CR45">2019</xref>)</td></tr><tr><td align="left" colspan="1" rowspan="1">ACE2</td><td align="left" colspan="1" rowspan="1">Aids entry of virus into cell</td><td align="left" colspan="1" rowspan="1">LRT</td><td align="left" colspan="1" rowspan="1">(Hoffmann et al. <xref ref-type="bibr" rid="CR41">2020</xref>)</td></tr><tr><td align="left" colspan="1" rowspan="1">Dipeptidyl peptidase 4 (DPP4)</td><td align="left" colspan="1" rowspan="1">Acts as the entry gate for virus spike protein in the host cell</td><td align="left" colspan="1" rowspan="1">LRT</td><td align="left" colspan="1" rowspan="1">(Pitocco et al. <xref ref-type="bibr" rid="CR85">2020</xref>)</td></tr></tbody></table><table-wrap-foot><p>Upper (U), respiratory tract: RT, Lower: L</p></table-wrap-foot></table-wrap></p><p id="Par6">The virus disseminates downward to the RT causing a vigorous innate immune response. The level of inflammatory chemokines (CXCL10) and cytokines is increased in bronchial airways which cause the recruitment of leukocytes, monocytes, eosinophils, natural killer (NK) cells and ILs that trigger gigantic inflammatory reaction (Mason <xref ref-type="bibr" rid="CR77">2020</xref>). The whole process affects gas exchange units of the lungs, which cause severe difficulty in breathing. High expression of inflammatory mediator&#8217;s causes narrowing of the airways and unwanted robust innate immune response which result in fever, cough, and pneumonia-like symptoms.</p><p id="Par7">It has been documented in COVID-19 infected patients that there is cerebral interference may occur in the early or later stage of the infection. The appearance of the COVID-19 virus in the general circulation allows it to reach the cerebral circulation, where even the virus spike protein interacts with ACE2 receptors expressed in capillary endothelium which further leads to harm the vessels and draw access to the brain. In the neuronal tissues, it interacts with ACE2 specific receptors in neurons, triggering a cycle of viral budding and neuronal damage without causing substantial inflammation (Palasca et al. <xref ref-type="bibr" rid="CR83">2018</xref>; Baig et al. <xref ref-type="bibr" rid="CR4">2020</xref>; Wang et al. <xref ref-type="bibr" rid="CR117">2020a</xref>). The endothelium of cerebral capillary ruptures followed by bleeding inside the cerebral tissue, may prove fatal to COVID-19 patients.</p><p id="Par8">The multifold transmission of different variants of COVID-19 emerges the intense demand for curative/prophylactic therapy to combat that dilemma of the present era. To date, there are few reports on possible preventive approaches or vaccine candidates. Clinical trials (CT) for COVID-19 therapies are being conducted, though, data from broad randomized clinical trials (RCT) are still deficient (Felsenstein et al. <xref ref-type="bibr" rid="CR30">2020</xref>). Due to time-consuming challenges of developing, testing, and manufacturing new medications, repurposing of proven medicinal remedies such as anti-inflammatory, antiviral, and anticoagulants offer a pragmatic alternative for symptomatic treatment of the COVID-19 infection (Harrison <xref ref-type="bibr" rid="CR37">2020</xref>).</p><p id="Par9">Currently, antiviral, immune-modulators, nucleoside analogues, neuraminidase inhibitors, protease inhibitors, and antimalarial drugs are some of the drug options used in the treatment of this fatal infection (Reche et al. <xref ref-type="bibr" rid="CR90">2020</xref>). Medicinal plants and their secondary metabolites such as flavonoids have exhibited substantial antiviral activity for different human viruses, including human immune deficiency virus (HIV), Middle East respiratory syndrome (MERS), hepatitis C virus, (HCV), SARS, and influenza viruses. Moreover, they have shown positive response in the management of COVID-19 (Adhikari et al. <xref ref-type="bibr" rid="CR1">2021</xref>). Presently, more than 300 COVID-19 vaccine projects are under different phases, of which 40 are evaluated in CT, 10 in Phase III and three have completed Phase III with positive consequences (Forni and Mantovani <xref ref-type="bibr" rid="CR32">2021</xref>); (Lurie et al. <xref ref-type="bibr" rid="CR74">2020</xref>). The current literature focuses on various available therapeutic options as well vaccines against COVID-19.</p></sec><sec id="Sec3"><title>Brief review of COVID-19 available therapies</title><p id="Par10">Various therapeutic options for COVID-19 are explored in Fig.&#160;<xref rid="Fig1" ref-type="fig">1</xref>.<fig id="Fig1" position="float" orientation="portrait"><label>Fig. 1</label><caption><p>Therapeutic strategy for COVID-19</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" id="MO1" position="float" orientation="portrait" xlink:href="10787_2021_850_Fig1_HTML.jpg"/></fig></p><sec id="Sec4"><title>Antiviral drugs</title><p id="Par11">The viral life cycle steps as well as virus entry and immune response are resilient targets for therapeutic drugs. The spike protein, ACE2, TMPRSS2, chymotrypsin like protease (3CLpro), RNA dependent RNA polymerase (RdRp), and papain-like protease (PLpro) are deliberated as chief targets for antiviral drugs against COVID-19 due to their high catalytic action and similarity with SARS-CoV-2 (Tallei et al. <xref ref-type="bibr" rid="CR108">2020</xref>). While certain mutations allow the virus to tightly affix to the host receptor and boost receptor transmissibility, which probably upsurge the infection transmission/prevalence. When the virus is inhaled, it comes in contact with epithelial cells of the nasal cavity and starts replicating and produce an innate immune response to a limited extent (Mason <xref ref-type="bibr" rid="CR77">2020</xref>).</p><p id="Par12">Remdesivir (wide spectrum), an adenosine nucleotide analogue and a wide spectrum antiviral drug developed in 2014 for the treatment of Ebola Virus (EBV), is now being used for COVID-19 infection by the U.S. Food and Drug Administration (FDA). Remdesivir stops replication and showed effective results in the treatment of later stages of COVID-19. It incorporates in single-stranded RNA of corona virus by polymerase enzyme, inhibit the addition of more RNA subunits and obstruct genome replication (Stebbing et al. <xref ref-type="bibr" rid="CR105">2020</xref>) as shown in Fig.&#160;<xref rid="Fig2" ref-type="fig">2</xref>.<fig id="Fig2" position="float" orientation="portrait"><label>Fig. 2</label><caption><p>Various allopathic treatments of COVID-19. Targeting viral entry mechanisms, possible methods for blocking ACE2 receptors, and antiviral drugs in replication stage [modified from (Majumder and Minko <xref ref-type="bibr" rid="CR75">2021</xref>)]. <italic toggle="yes">scFv</italic> single-chain variable fragment, <italic toggle="yes">TCZ</italic> tocilizumab</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" id="MO2" position="float" orientation="portrait" xlink:href="10787_2021_850_Fig2_HTML.jpg"/></fig></p><p id="Par13">Favipiravir (synthetic prodrug), originally a purine nucleotide, effectively inhibits RNA dependent RNA polymerase (RdRp) and averts virus production. It is used against influenza and EBV viruses and has shown broad activity against many other RNA virus (SARS-CoV-2) (Udwadia et al. <xref ref-type="bibr" rid="CR111">2021</xref>).</p><p id="Par14">The disulfiram, a disulphide, an authorized medicine for alcohol misuse, is widely acclaimed to block the MERS and SARS PLpro, now present a potential role against SARS-Cov2. It inhibits the release of viral genome by hindering the papain-like protease in SARS-CoV2 (Majumder and Minko <xref ref-type="bibr" rid="CR75">2021</xref>; Beck et al. <xref ref-type="bibr" rid="CR6">2020</xref>). The combination of disulfiram/ebselen and remdesivir is found effective against COVID-19 by hindering replication step in in vitro study (Chen et al. <xref ref-type="bibr" rid="CR13">2021</xref>). This combination is a multitarget strategy effective against all types of corona viruses with conserved zinc (Zn<sup>+</sup>) ejection site.</p><p id="Par15">Various therapeutic drugs target sites and action in COVID-19 are illustrated in Fig.&#160;<xref rid="Fig2" ref-type="fig">2</xref> and Table <xref rid="Tab2" ref-type="table">2</xref>.<table-wrap id="Tab2" position="float" orientation="portrait"><label>Table 2</label><caption><p>Current allopathic therapies and their actions and potential adverse effects in COVID-19</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" colspan="1" rowspan="1">Drug<break/>class</th><th align="left" colspan="1" rowspan="1">Therapeutic drug</th><th align="left" colspan="1" rowspan="1">Actions</th><th align="left" colspan="1" rowspan="1">Adverse effects</th><th align="left" colspan="1" rowspan="1">References</th></tr></thead><tbody><tr><td align="left" colspan="1" rowspan="1">Antimalarial</td><td align="left" colspan="1" rowspan="1">Chloroquine phosphate</td><td align="left" colspan="1" rowspan="1"><p>Glycosylation inhibitor</p><p>Proteolytic, inhibition of cytokines production, autophagy, lysosomal and host cell activity</p></td><td align="left" colspan="1" rowspan="1"><p>Cramps in the abdomen, diarrhea, anorexia</p><p>CVD symptoms, hypoglycemia, retinal damage, neuropsychiatric toxicity, Idiosyncratic reactions</p></td><td align="left" colspan="1" rowspan="1">(Vijayvargiya et al. <xref ref-type="bibr" rid="CR113">2020</xref>)</td></tr><tr><td align="left" rowspan="2" colspan="1">Antiviral</td><td align="left" colspan="1" rowspan="1">Remdesivir</td><td align="left" colspan="1" rowspan="1">Inhibition of RNA polymerase</td><td align="left" colspan="1" rowspan="1">Transaminases elevation, kidney damage</td><td align="left" colspan="1" rowspan="1">(Stebbing et al. <xref ref-type="bibr" rid="CR105">2020</xref>)</td></tr><tr><td align="left" colspan="1" rowspan="1">Favipiravir</td><td align="left" colspan="1" rowspan="1">Inhibition of RNA polymerase</td><td align="left" colspan="1" rowspan="1">Hyperuricemia, diarrhoea, &#8593;Transaminases, &#8595;Neutrophil count</td><td align="left" colspan="1" rowspan="1">(Udwadia et al. <xref ref-type="bibr" rid="CR111">2021</xref>)</td></tr><tr><td align="left" colspan="1" rowspan="1">Monoclonal antibody</td><td align="left" colspan="1" rowspan="1">Tocilizumab</td><td align="left" colspan="1" rowspan="1">Block IL-6 receptor alpha subunit</td><td align="left" colspan="1" rowspan="1">GIT disorders, skin/subcutaneous infections and altered liver enzymes</td><td align="left" colspan="1" rowspan="1">(Luo et al. <xref ref-type="bibr" rid="CR73">2020b</xref>)</td></tr><tr><td align="left" colspan="1" rowspan="1">Anti-HIV</td><td align="left" colspan="1" rowspan="1">Lopinavir/ritonavir</td><td align="left" colspan="1" rowspan="1">Inhibit 3C-like proteinase (3CLpro) and papain-like proteinase (PLpro) resulted in immature virus particle in COVID-19</td><td align="left" colspan="1" rowspan="1"><p>GIT intolerance, pancreatitis,</p><p>abnormalities in cardiac conduction, hepatotoxicity</p></td><td align="left" colspan="1" rowspan="1">(Consortium WST&#160;<xref ref-type="bibr" rid="CR15">2021</xref>)</td></tr><tr><td align="left" colspan="1" rowspan="1">Antiprotease</td><td align="left" colspan="1" rowspan="1">Disulfiram</td><td align="left" colspan="1" rowspan="1">Papain like protease inhibitor</td><td align="left" colspan="1" rowspan="1">Hypotension, tachycardia</td><td align="left" colspan="1" rowspan="1">(Majumder and Minko <xref ref-type="bibr" rid="CR75">2021</xref>)</td></tr></tbody></table><table-wrap-foot><p>Gastrointestinal: GIT, cardiovascular disorders: CVD</p></table-wrap-foot></table-wrap></p></sec><sec id="Sec5"><title>Immuno-modulators</title><p id="Par16">Tocilizumab (TCZ), anti-IL-6 monoclonal antibody, is now used for COVID-19 patients (Luo et al. <xref ref-type="bibr" rid="CR73">2020b</xref>). It blocks cytokine storm and potentially stabilizes the condition of patients. But it is preferred to use for critically ill patients in repeated doses (Wu et al. <xref ref-type="bibr" rid="CR122">2021</xref>).</p><p id="Par17">The TCZ in combination with lopinavir and methylprednisolone is also suggested for the treatment of COVID-19 patients especially in severe cases (David J Cennimo <xref ref-type="bibr" rid="CR23">2020</xref>). IL-6 is a multipurpose cytokine that is involved in B-cell differentiation, thrombopoiesis stimulation, protein synthesis and also bone resorption. It prevents the interaction of interleukin with signal transducer glycoprotein (130 complexes) and IL-6R. As a result, after involving the Janus-kinase-signal transducer and activator of transcription proteins signalling pathway, it inhibits cis and trans signalling cascades (Biggioggero et al. <xref ref-type="bibr" rid="CR7">2019</xref>).</p><p id="Par18">Corticosteroids are also used in the management of COVID-19. They block inflammatory storm especially in lungs, which otherwise could lead to acute lung injury and acute breathing distress syndrome (ARDS) (Russell et al. <xref ref-type="bibr" rid="CR91">2020</xref>). Dexamethasone (Dex) is the very first lifesaving drug showed therapeutic effectiveness in COVID-19. In the largest COVID-19 RCT, the so-called RECOVERY trial, six interventions were under evaluation including Dex, hydroxychloroquine, Azithromycin, anti-HIV drug combination lopinavir&#8211;ritonavir, TCZ, and healed patient convalescent plasma. No clinical benefit was reported for hydroxychloroquine and lopinavir&#8211;ritonavir in hospitalized patients in the first and third statements published by the RECOVERY chief investigators. The second quote indicated Dex (6&#160;mg/day; orally or intravenous infusion administered for 10&#160;days) reduced the numbers of COVID-19 deaths in intensive care unit (ICU) patients with oxygen therapy (35%). The death rate was decreased 20% under oxygen therapy. Moreover, nanodelivery of Dex is assumed to be more efficacious than conventional in COVID-19 patients (Lammers et al. <xref ref-type="bibr" rid="CR62">2020</xref>).</p><p id="Par19">Chloroquine, an antimalarial agent with anti-inflammatory and immunomodulatory effects, had acquired great attention as a possible therapeutic alternative for COVID-19 treatment (Vijayvargiya et al. <xref ref-type="bibr" rid="CR113">2020</xref>).</p></sec><sec id="Sec6"><title>Antibody and convalescent plasma (CP) therapy</title><p id="Par20">The CP therapy was suggested by the FDA (21 Apr 2021) in emergency use authorization (EUA) for hospitalized COVID-19 patients. The high titer CP was recommended in the EAU against COVID-19 in hospitalized and immune deficient patients, nevertheless use of low titer CP is restricted in EUA (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://www.ncbi.nlm.nih.gov">http://www.ncbi.nlm.nih.gov</ext-link>). The generation of recombinant human monoclonal antibody (mAb) provides a path to neutralize COVID-19 virus by interacting with the spike protein (S glycoprotein) present on its surface. CR3022, SARS-CoV specific antibody, binds to the receptor-binding domain (RBD), recognized as a therapeutic candidate against COVID-19 infection (Wang et al. <xref ref-type="bibr" rid="CR117">2020a</xref>). Other monoclonal antibodies like 47D11, m396 and CR3014 are also used for the treatment of corona virus infection (Zhang and Liu <xref ref-type="bibr" rid="CR129">2020</xref>; Yuan et al. <xref ref-type="bibr" rid="CR128">2020</xref>).</p></sec><sec id="Sec7"><title>Natural products</title><p id="Par21">The medicinal plants and phytocomponents exhibited synergistic effects against the COVID-19 and boosted the immune system such as <italic toggle="yes">Citrus limon, Nigella sativa</italic>, <italic toggle="yes">Withania somnifera,</italic> etc. Previous studies reported the immune booster effect of these plants in COVID-19 infection that acted by binding and hindering to 3CLpro, main protease (Mpro), papain-like protease (PLpro), and spike protein in COVID-19 (Tallei et al. <xref ref-type="bibr" rid="CR108">2020</xref>). The edible foods such as cinnamon, pepper, olive, black nightshade, passion fruit, and grapes are also effective in prophylaxis and treatment of COVID-19. These plants have ACE2 inhibition activity and have been used in coronavirus patients with comorbidities of hypertension and diabetes (da Silva Antonio et al. <xref ref-type="bibr" rid="CR19">2020</xref>; Daskaya-Dikmen et al. <xref ref-type="bibr" rid="CR22">2017</xref>). Some plants have been used as 3C-like protease (3CLpro) inhibitors such as lemon, balm, lavender, geranium, basil, cinnamon, and ginger.</p><p id="Par22">Quercetin, strong antioxidant, is a flavonoid derivative isolated from several fruits and vegetables such as <italic toggle="yes">Foeniculum vulgare</italic>, and <italic toggle="yes">Allium cepa</italic>. It blocked (82%) SARS-CoV protease (Huang et al. <xref ref-type="bibr" rid="CR44">2020</xref>). It showed antiviral properties against SARS-CoV-2 in docking study using 3CLpro and other crucial targets (Tallei et al. <xref ref-type="bibr" rid="CR108">2020</xref>). Previously, it was reported that quercetin binds to spike protein, ACE2, RdRp, and PLpro, which assured its anti-SARS-CoV-2 potential.</p><p id="Par23">Andrographolide (diterpene), an efficient antiviral, is extracted from <italic toggle="yes">Andrographis paniculata</italic> and binds to spike protein, ACE2, 3CLpro, RdRp, and PLpro (Kishore et al. <xref ref-type="bibr" rid="CR59">2017</xref>) that indicated its possible efficacy against COVID-19. Glycyrrhizic acid, a polyphenol derived from <italic toggle="yes">Glycyrrhiza glabra</italic> root binds to ACE2 receptor hence effective against SARS-CoV, and SARS-CoV-2 (Luo et al. <xref ref-type="bibr" rid="CR72">2020a</xref>). Furthermore, it inhibits immune hyperactivation and production of cytokine storm (He et al. <xref ref-type="bibr" rid="CR39">2020</xref>). Baicalin, is a flavone glycoside and non-peptidomimetic inhibitors of SARS-CoV-2 3CLpro (Chen et al. <xref ref-type="bibr" rid="CR12">2017</xref>).</p><p id="Par24">Patchouli alcohol (PA), a sesquiterpene has antiviral, anti-inflammatory, immunomodulatory, antioxidant, and antitumor properties (Hu et al. <xref ref-type="bibr" rid="CR43">2017</xref>). The molecular docking showed the binding of PA to SARS-CoV-2 related targets and explored the satisfactory binding of PA to RdRp which assured its antiviral effect.</p><p id="Par25">Luteolin, a naturally occurring flavonoid, has anti-cancer, anti-inflammatory, antioxidant, antiviral, and heart-protective properties (Fasuan et al. <xref ref-type="bibr" rid="CR28">2018</xref>). SARS-CoV 3CLpro was inhibited by luteolin derived from <italic toggle="yes">Torreya Nucifera</italic> (Ryu et al. <xref ref-type="bibr" rid="CR92">2010</xref>). Various phytochemicals and their target sites for COVID-19 therapy are mentioned in Table <xref rid="Tab3" ref-type="table">3</xref> and Fig.&#160;<xref rid="Fig3" ref-type="fig">3</xref>.<table-wrap id="Tab3" position="float" orientation="portrait"><label>Table 3</label><caption><p>Natural compounds and their potent mechanism of action against COVID-19</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" colspan="1" rowspan="1">Natural Compounds</th><th align="left" colspan="1" rowspan="1">Class</th><th align="left" colspan="1" rowspan="1">Source</th><th align="left" colspan="1" rowspan="1">Mechanism of action</th><th align="left" colspan="1" rowspan="1">References</th></tr></thead><tbody><tr><td align="left" colspan="1" rowspan="1">Quercetin</td><td align="left" colspan="1" rowspan="1">Flavonol</td><td align="left" colspan="1" rowspan="1"><italic toggle="yes">Dysosma pleiantha</italic></td><td align="left" colspan="1" rowspan="1">Hinders (&#8201;&#215;) CLp and block virus entry into the cell</td><td align="left" colspan="1" rowspan="1">(Nguyen et al. <xref ref-type="bibr" rid="CR80">2012</xref>; Al Hamdany et al. <xref ref-type="bibr" rid="CR2">2019</xref>)</td></tr><tr><td align="left" colspan="1" rowspan="1">Andrographolide</td><td align="left" colspan="1" rowspan="1">Diterpenoid</td><td align="left" colspan="1" rowspan="1"><italic toggle="yes">Andrographis paniculata</italic></td><td align="left" colspan="1" rowspan="1">&#8201;&#215;&#8201;CLp and virus-induced stimulation of RLRs signalling pathway</td><td align="left" colspan="1" rowspan="1">(Enmozhi et al. <xref ref-type="bibr" rid="CR26">2021</xref>; Rao et al. <xref ref-type="bibr" rid="CR88">2004</xref>; Malik et al. <xref ref-type="bibr" rid="CR76">2021</xref>)</td></tr><tr><td align="left" colspan="1" rowspan="1">Glycyrrhizic acid</td><td align="left" colspan="1" rowspan="1">Polyphenols</td><td align="left" colspan="1" rowspan="1"><italic toggle="yes">Glycyrrhiza glabra</italic></td><td align="left" colspan="1" rowspan="1">&#8201;&#215;&#8201;replication and permeation of the virus</td><td align="left" colspan="1" rowspan="1">(Luo et al. <xref ref-type="bibr" rid="CR72">2020a</xref>; Petramfar et al. <xref ref-type="bibr" rid="CR84">2020</xref>; Nazari et al. <xref ref-type="bibr" rid="CR79">2017</xref>)</td></tr><tr><td align="left" colspan="1" rowspan="1">Baicalin</td><td align="left" colspan="1" rowspan="1">Flavone glycoside</td><td align="left" colspan="1" rowspan="1"><italic toggle="yes">Radix Scutellariae</italic></td><td align="left" colspan="1" rowspan="1">&#8201;&#215;&#8201;CLp</td><td align="left" colspan="1" rowspan="1">(Su et al. <xref ref-type="bibr" rid="CR106">2020</xref>; Okoshi et al. <xref ref-type="bibr" rid="CR81">2021</xref>)</td></tr><tr><td align="left" colspan="1" rowspan="1">Patchouli alcohol</td><td align="left" colspan="1" rowspan="1">Sesquiterpene alcohol</td><td align="left" colspan="1" rowspan="1"><italic toggle="yes">Pogostemon cablin</italic></td><td align="left" colspan="1" rowspan="1">Bind with RdRp and produce inhibitory effects</td><td align="left" colspan="1" rowspan="1">(Yu et al. <xref ref-type="bibr" rid="CR127">2019</xref>; Xu et al. <xref ref-type="bibr" rid="CR124">2017</xref>)</td></tr><tr><td align="left" colspan="1" rowspan="1">Luteolin</td><td align="left" colspan="1" rowspan="1">Flavone</td><td align="left" colspan="1" rowspan="1"><p><italic toggle="yes">Cuminum cyminum</italic></p><p><italic toggle="yes">Torreya nucifera</italic></p></td><td align="left" colspan="1" rowspan="1">&#8201;&#215;&#8201;CLp and blocks viral replication in early stage of contamination</td><td align="left" colspan="1" rowspan="1">(Yan et al. <xref ref-type="bibr" rid="CR125">2019</xref>; Kempuraj et al. <xref ref-type="bibr" rid="CR55">2021</xref>; Goodarzi et al. <xref ref-type="bibr" rid="CR35">2020</xref>)</td></tr><tr><td align="left" colspan="1" rowspan="1">Hesperidin</td><td align="left" colspan="1" rowspan="1">Flavanone glycoside</td><td align="left" colspan="1" rowspan="1"><italic toggle="yes">Citrus sinensis</italic></td><td align="left" colspan="1" rowspan="1">&#8201;&#215;&#8201;CLp</td><td align="left" colspan="1" rowspan="1">(Joshi et al. <xref ref-type="bibr" rid="CR52">2021</xref>; Sim <xref ref-type="bibr" rid="CR103">2019</xref>; Selmi et al. <xref ref-type="bibr" rid="CR97">2017</xref>)</td></tr><tr><td align="left" colspan="1" rowspan="1">Emodin</td><td align="left" colspan="1" rowspan="1">Anthraquinone</td><td align="left" colspan="1" rowspan="1"><italic toggle="yes">Aloe vera</italic></td><td align="left" colspan="1" rowspan="1">Blocks the SARS-CoV2 spike protein and ACE2 interaction and reduce virus release</td><td align="left" colspan="1" rowspan="1">(Schwarz et al. <xref ref-type="bibr" rid="CR95">2011</xref>; Kumar et al. <xref ref-type="bibr" rid="CR60">2017</xref>)</td></tr><tr><td align="left" colspan="1" rowspan="1">Resveratrol</td><td align="left" colspan="1" rowspan="1">Phenol</td><td align="left" colspan="1" rowspan="1"><italic toggle="yes">Vitis vinifera</italic></td><td align="left" colspan="1" rowspan="1">&#8201;&#215;&#8201;RNA and nucleocapsid expression</td><td align="left" colspan="1" rowspan="1">(Lin et al. <xref ref-type="bibr" rid="CR67">2017</xref>; Hasan and Bae <xref ref-type="bibr" rid="CR38">2017</xref>)</td></tr><tr><td align="left" colspan="1" rowspan="1">Kaempferol</td><td align="left" colspan="1" rowspan="1">Flavanol</td><td align="left" colspan="1" rowspan="1"><italic toggle="yes">Dysosma pleiantha</italic></td><td align="left" colspan="1" rowspan="1">&#8201;&#215;&#8201;3a channel protein</td><td align="left" colspan="1" rowspan="1">(Karuppaiya and Tsay <xref ref-type="bibr" rid="CR53">2020</xref>)</td></tr><tr><td align="left" colspan="1" rowspan="1">Lignan</td><td align="left" colspan="1" rowspan="1">Polyphenols</td><td align="left" colspan="1" rowspan="1"><italic toggle="yes">Phyllanthus tenellus Roxb</italic></td><td align="left" colspan="1" rowspan="1">&#8201;&#215;&#8201;virus replication and CLp</td><td align="left" colspan="1" rowspan="1">(Lee et al. <xref ref-type="bibr" rid="CR64">2015</xref>; Szopa et al. <xref ref-type="bibr" rid="CR107">2021</xref>)</td></tr><tr><td align="left" colspan="1" rowspan="1">Betulinic acid</td><td align="left" colspan="1" rowspan="1">Triterpenoid</td><td align="left" colspan="1" rowspan="1"><italic toggle="yes">Yarrowia lipolytica</italic></td><td align="left" colspan="1" rowspan="1">&#8201;&#215;&#8201;virus replication and CLp</td><td align="left" colspan="1" rowspan="1">(Hordyjewska et al. <xref ref-type="bibr" rid="CR42">2019</xref>; Jin et al. <xref ref-type="bibr" rid="CR50">2019</xref>)</td></tr><tr><td align="left" colspan="1" rowspan="1">Tanshinone</td><td align="left" colspan="1" rowspan="1">Diterpene quinone</td><td align="left" colspan="1" rowspan="1"><italic toggle="yes">Salvia xantocheila</italic></td><td align="left" colspan="1" rowspan="1">&#8201;&#215;&#8201;CLp and PLpro</td><td align="left" colspan="1" rowspan="1">(Hirai et al. <xref ref-type="bibr" rid="CR40">2015</xref>; Fotovvat et al. <xref ref-type="bibr" rid="CR33">2017</xref>)</td></tr><tr><td align="left" colspan="1" rowspan="1">Cryptotanshinone</td><td align="left" colspan="1" rowspan="1">Diterpene</td><td align="left" colspan="1" rowspan="1"><italic toggle="yes">Salvia miltiorrhiza</italic></td><td align="left" colspan="1" rowspan="1">&#8201;&#215;&#8201;CLp and PLpro</td><td align="left" colspan="1" rowspan="1">(Jiang et al. <xref ref-type="bibr" rid="CR48">2017</xref>; Chang et al. <xref ref-type="bibr" rid="CR10">2018</xref>)</td></tr><tr><td align="left" colspan="1" rowspan="1">Curcumin</td><td align="left" colspan="1" rowspan="1">Flavonoid</td><td align="left" colspan="1" rowspan="1"><italic toggle="yes">Curcuma longa</italic></td><td align="left" colspan="1" rowspan="1">&#8201;&#215;&#8201;virus replication and CLp</td><td align="left" colspan="1" rowspan="1">(Wen et al. <xref ref-type="bibr" rid="CR119">2007</xref>; Cione et al. <xref ref-type="bibr" rid="CR14">2020</xref>)</td></tr><tr><td align="left" colspan="1" rowspan="1">Shikonin</td><td align="left" colspan="1" rowspan="1">Naphthoquinone</td><td align="left" colspan="1" rowspan="1"><italic toggle="yes">Lithospermum officinale</italic></td><td align="left" colspan="1" rowspan="1">&#8201;&#215;&#8201;CLp</td><td align="left" colspan="1" rowspan="1">(Jin et al. <xref ref-type="bibr" rid="CR51">2020</xref>; Mollaei et al. <xref ref-type="bibr" rid="CR78">2019</xref>)</td></tr><tr><td align="left" colspan="1" rowspan="1">Matrine</td><td align="left" colspan="1" rowspan="1">Alkaloid</td><td align="left" colspan="1" rowspan="1"><italic toggle="yes">Aspergillus terreus</italic></td><td align="left" colspan="1" rowspan="1">Improves altered parameters and clinical symptoms</td><td align="left" colspan="1" rowspan="1">(Liu et al. <xref ref-type="bibr" rid="CR68">2021</xref>; Zhang et al. <xref ref-type="bibr" rid="CR131">2017</xref>)</td></tr></tbody></table><table-wrap-foot><p><italic toggle="yes">Hinders</italic>&#8201;&#215;&#8201;, <italic toggle="yes">HA</italic> hepatitis A, <italic toggle="yes">RLRs</italic> retinoic acid inducible gene I-like receptors, <italic toggle="yes">CLp</italic> chymotrypsin like protease, <italic toggle="yes">ACE2</italic> angiotensin-converting enzyme</p></table-wrap-foot></table-wrap><fig id="Fig3" position="float" orientation="portrait"><label>Fig. 3</label><caption><p>A diagrammatic illustration of key targets for natural products as anti-COVID-19</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" id="MO3" position="float" orientation="portrait" xlink:href="10787_2021_850_Fig3_HTML.jpg"/></fig></p></sec><sec id="Sec8"><title>COVID-19 vaccines</title><p id="Par26">Vaccines are necessary for controlling the severity and spreading of infection. There are many vaccination strategies tested in animals such as live attenuated virus, inactivated virus, recombinant DNA, viral vectors, subunit vaccines and protein vaccines. These studies are still continued and can take months or years to complete. Nowadays researchers are busy in developing vaccines against pandemic COVID-19 but the process of making a new drug entity and a vaccine is time taking (Khanal et al. <xref ref-type="bibr" rid="CR57">2021</xref>). Most of the antiCOVID-19 vaccines safety studies excludes older people due to associated comorbidities and weakness such as AstraZeneca, Moderna, and Pfizer have scarce data regarding vaccines safety in aged and sensitive individuals (Soiza et al. <xref ref-type="bibr" rid="CR104">2021</xref>). Centre for disease control and prevention (CDA) does not recommend one anti-COVID-19 vaccine over the other.</p><p id="Par27">The detail of several COVID-19 vaccines, manufacturer, adverse effects, efficacy, safety, dose and their mechanism are mentioned in Table <xref rid="Tab4" ref-type="table">4</xref>, Figs.&#160;<xref rid="Fig4" ref-type="fig">4</xref> and <xref rid="Fig5" ref-type="fig">5</xref>. Whereas, efficacy (%) of different available COVID-19 vaccines is shown in Fig.&#160;<xref rid="Fig6" ref-type="fig">6</xref>.<table-wrap id="Tab4" position="float" orientation="portrait"><label>Table 4</label><caption><p>Available vaccines against COVID-19 safety and efficacy in terms of clinical trials</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" colspan="1" rowspan="1">Sr No</th><th align="left" colspan="1" rowspan="1">COVID-19 vaccines</th><th align="left" colspan="1" rowspan="1">Brand name of COVID-19 vaccines</th><th align="left" colspan="1" rowspan="1">Other vaccine name</th><th align="left" colspan="1" rowspan="1">Vaccine type</th><th align="left" colspan="1" rowspan="1">Manufacturer</th><th align="left" colspan="1" rowspan="1">Clinical<break/>trial phase</th><th align="left" colspan="1" rowspan="1">Number of doses/route of administration</th><th align="left" colspan="1" rowspan="1">Immunity develop</th><th align="left" colspan="1" rowspan="1">People who can be vaccinated</th><th align="left" colspan="1" rowspan="1">Adverse<break/>effect</th><th align="left" colspan="1" rowspan="1">Efficacy (%)</th><th align="left" colspan="1" rowspan="1">References</th></tr></thead><tbody><tr><td align="left" colspan="1" rowspan="1">1</td><td align="left" colspan="1" rowspan="1">SinoVac</td><td align="left" colspan="1" rowspan="1">SinoVac</td><td align="left" colspan="1" rowspan="1">CoronaVac</td><td align="left" colspan="1" rowspan="1">SARS-CoV-2 vaccine inactivated with aluminium hydroxide</td><td align="left" colspan="1" rowspan="1">Wuhan Institute of Biological products, China/Sinovac Biotech, China</td><td align="left" colspan="1" rowspan="1">3</td><td align="left" colspan="1" rowspan="1">0.5&#160;ml divided into 2 doses-14&#160;days apart/ IM</td><td align="left" colspan="1" rowspan="1">Post 2&#160;weeks of second dose</td><td align="left" colspan="1" rowspan="1">18&#160;years and above</td><td align="left" colspan="1" rowspan="1">Pain, fever</td><td align="left" colspan="1" rowspan="1">50</td><td align="left" colspan="1" rowspan="1">(Zhang et al. <xref ref-type="bibr" rid="CR132">2020</xref>; Baden et al. <xref ref-type="bibr" rid="CR3">2021</xref>; Gao et al. <xref ref-type="bibr" rid="CR34">2020</xref>)</td></tr><tr><td align="left" colspan="1" rowspan="1">2</td><td align="left" colspan="1" rowspan="1">Pfizer-BioNTech</td><td align="left" colspan="1" rowspan="1">Comirnaty</td><td align="left" colspan="1" rowspan="1">BNT162B1</td><td align="left" colspan="1" rowspan="1">mRNA vaccine</td><td align="left" colspan="1" rowspan="1">Pfizer, INC., and BioNTech, Germany</td><td align="left" colspan="1" rowspan="1">3</td><td align="left" colspan="1" rowspan="1">0.3&#160;ml divided in 2 doses&#8212;21&#160;days apart/ IM</td><td align="left" colspan="1" rowspan="1">Post 2&#160;weeks of second dose</td><td align="left" colspan="1" rowspan="1">12&#160;years and above</td><td align="left" colspan="1" rowspan="1">Pain, redness, joint pain, muscle pain, paroxysmal ventricular arrhythmia</td><td align="left" colspan="1" rowspan="1">95</td><td align="left" colspan="1" rowspan="1">(Ewer et al. <xref ref-type="bibr" rid="CR27">2021</xref>; Polack et al. <xref ref-type="bibr" rid="CR86">2020</xref>)</td></tr><tr><td align="left" colspan="1" rowspan="1">3</td><td align="left" colspan="1" rowspan="1">Moderna</td><td align="left" colspan="1" rowspan="1">Moderna</td><td align="left" colspan="1" rowspan="1">mRNA1273</td><td align="left" colspan="1" rowspan="1">mRNA vaccine</td><td align="left" colspan="1" rowspan="1">Moderna/National institute of allergy and infectious diseases</td><td align="left" colspan="1" rowspan="1">3</td><td align="left" colspan="1" rowspan="1">0.5&#160;ml divided into 2 doses&#8212;21&#160;days apart/IM</td><td align="left" colspan="1" rowspan="1">Post 2&#160;weeks of getting dose</td><td align="left" colspan="1" rowspan="1">18&#160;years and above</td><td align="left" colspan="1" rowspan="1">Local and systemic reaction</td><td align="left" colspan="1" rowspan="1">94</td><td align="left" colspan="1" rowspan="1">(Jackson et al. <xref ref-type="bibr" rid="CR46">2020</xref>; Baden et al. <xref ref-type="bibr" rid="CR3">2021</xref>)</td></tr><tr><td align="left" colspan="1" rowspan="1">4</td><td align="left" colspan="1" rowspan="1">Jansseen COVID-19 Vaccine</td><td align="left" colspan="1" rowspan="1">Janssen/J&amp;J</td><td align="left" colspan="1" rowspan="1">Ad26COVS1</td><td align="left" colspan="1" rowspan="1">Virus vector vaccine</td><td align="left" colspan="1" rowspan="1"><p>Janssen Pharmaceutical</p><p>Companies, Netherland</p></td><td align="left" colspan="1" rowspan="1">3</td><td align="left" colspan="1" rowspan="1">2 doses&#8212;21&#160;days apart/IM</td><td align="left" colspan="1" rowspan="1">Post 2&#160;weeks of second dose</td><td align="left" colspan="1" rowspan="1">18&#160;years and above</td><td align="left" colspan="1" rowspan="1">Irritation</td><td align="left" colspan="1" rowspan="1">73.1</td><td align="left" colspan="1" rowspan="1">(Corbett et al. <xref ref-type="bibr" rid="CR16">2020</xref>; Sadoff et al. <xref ref-type="bibr" rid="CR93">2021</xref>)</td></tr><tr><td align="left" colspan="1" rowspan="1">5</td><td align="left" colspan="1" rowspan="1">AstraZeneca</td><td align="left" colspan="1" rowspan="1">Vaxzevria/ Covishield</td><td align="left" colspan="1" rowspan="1">ChAdOx1 nCoV-19/AZD1222</td><td align="left" colspan="1" rowspan="1">Virus vector vaccine</td><td align="left" colspan="1" rowspan="1">AstraZeneca, Oxford, England/Serum institute of India, Pune</td><td align="left" colspan="1" rowspan="1">3</td><td align="left" colspan="1" rowspan="1">2 doses intermittently, each dose 12&#160;weeks apart/IM</td><td align="left" colspan="1" rowspan="1">Post 2&#160;weeks of second dose</td><td align="left" colspan="1" rowspan="1">18&#160;years and above</td><td align="left" colspan="1" rowspan="1">A pathogenic PF4-dependent syndrome may develop</td><td align="left" colspan="1" rowspan="1">70.4</td><td align="left" colspan="1" rowspan="1">(Folegatti et al. <xref ref-type="bibr" rid="CR31">2020</xref>; Voysey et al. <xref ref-type="bibr" rid="CR114">2021</xref>; Scully et al. <xref ref-type="bibr" rid="CR96">2021</xref>)</td></tr><tr><td align="left" colspan="1" rowspan="1">6</td><td align="left" colspan="1" rowspan="1">SputnikV</td><td align="left" colspan="1" rowspan="1">Sputnik V</td><td align="left" colspan="1" rowspan="1">Gram Covid Vac</td><td align="left" colspan="1" rowspan="1">Virus vector vaccine</td><td align="left" colspan="1" rowspan="1">Gamaleya Research Institute, Russia</td><td align="left" colspan="1" rowspan="1">3</td><td align="left" colspan="1" rowspan="1">0.5&#160;ml in 2 doses&#8212;21&#160;days apart</td><td align="left" colspan="1" rowspan="1">Post 2&#160;weeks of second dose</td><td align="left" colspan="1" rowspan="1">18&#160;years and above</td><td align="left" colspan="1" rowspan="1">Flu-like illness, headache, asthenia, renal colic, deep vein thrombosis</td><td align="left" colspan="1" rowspan="1">91</td><td align="left" colspan="1" rowspan="1">(Logunov et al. <xref ref-type="bibr" rid="CR69">2020</xref>, <xref ref-type="bibr" rid="CR70">2021</xref>)</td></tr><tr><td align="left" colspan="1" rowspan="1">7</td><td align="left" colspan="1" rowspan="1">Novavax</td><td align="left" colspan="1" rowspan="1">Covavax</td><td align="left" colspan="1" rowspan="1">NVX-CoV2373</td><td align="left" colspan="1" rowspan="1">Virus resemble vaccine particles (adjuvanted recombinant protein nanoparticle)</td><td align="left" colspan="1" rowspan="1">Novavax Biotechnology company, America</td><td align="left" colspan="1" rowspan="1">3</td><td align="left" colspan="1" rowspan="1">2 doses&#8212;21&#160;days apart/IM</td><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1">18&#160;years and above</td><td align="left" colspan="1" rowspan="1">Fatigue, headache, pain</td><td align="left" colspan="1" rowspan="1">96</td><td align="left" colspan="1" rowspan="1">(Callaway and Mallapaty <xref ref-type="bibr" rid="CR9">2021</xref>; Shinde et al. <xref ref-type="bibr" rid="CR101">2021</xref>)</td></tr><tr><td align="left" colspan="1" rowspan="1">8</td><td align="left" colspan="1" rowspan="1">Sinopharm</td><td align="left" colspan="1" rowspan="1">Sinopharm</td><td align="left" colspan="1" rowspan="1">BBIBP-CorV</td><td align="left" colspan="1" rowspan="1">Inactivated virus vaccine</td><td align="left" colspan="1" rowspan="1">Beijing Bio-Institute of Biological Products, China</td><td align="left" colspan="1" rowspan="1">3</td><td align="left" colspan="1" rowspan="1">2 doses&#8212;21&#160;days apart</td><td align="left" colspan="1" rowspan="1">Post-vaccination</td><td align="left" colspan="1" rowspan="1">18&#160;years and above</td><td align="left" colspan="1" rowspan="1">Mild cellulitis</td><td align="left" colspan="1" rowspan="1">79</td><td align="left" colspan="1" rowspan="1">(Xia et al. <xref ref-type="bibr" rid="CR123">2021</xref>; Keech et al. <xref ref-type="bibr" rid="CR54">2020</xref>)</td></tr><tr><td align="left" colspan="1" rowspan="1">9</td><td align="left" colspan="1" rowspan="1">Covaxin</td><td align="left" colspan="1" rowspan="1">Covaxin</td><td align="left" colspan="1" rowspan="1">BBV152</td><td align="left" colspan="1" rowspan="1">Inactivated virus vaccine</td><td align="left" colspan="1" rowspan="1">Bharat Biotech, India</td><td align="left" colspan="1" rowspan="1">3</td><td align="left" colspan="1" rowspan="1">2 doses&#8212;4&#160;weeks apart</td><td align="left" colspan="1" rowspan="1">Post-vaccination of 2nd dose</td><td align="left" colspan="1" rowspan="1">18&#160;years and above</td><td align="left" colspan="1" rowspan="1">Pain at site of injection</td><td align="left" colspan="1" rowspan="1">81</td><td align="left" colspan="1" rowspan="1">(Ella et al. <xref ref-type="bibr" rid="CR25">2021</xref>)</td></tr><tr><td align="left" colspan="1" rowspan="1">10</td><td align="left" colspan="1" rowspan="1">CanSino</td><td align="left" colspan="1" rowspan="1">Convidecia</td><td align="left" colspan="1" rowspan="1">Ad5-nCoV</td><td align="left" colspan="1" rowspan="1">Vector vaccine</td><td align="left" colspan="1" rowspan="1">CanSino Biologics, China</td><td align="left" colspan="1" rowspan="1">3</td><td align="left" colspan="1" rowspan="1">One shot</td><td align="left" colspan="1" rowspan="1">Post-vaccination</td><td align="left" colspan="1" rowspan="1">18&#160;years and above</td><td align="left" colspan="1" rowspan="1">Pain at site of injection</td><td align="left" colspan="1" rowspan="1">65.7</td><td align="left" colspan="1" rowspan="1">(Sharma et al. <xref ref-type="bibr" rid="CR98">2020</xref>)</td></tr></tbody></table></table-wrap><fig id="Fig4" position="float" orientation="portrait"><label>Fig. 4</label><caption><p>Illustration of several COVID-19 vaccines and their mechanism (</p><p>modified from Dash et al. <xref ref-type="bibr" rid="CR21">2021</xref>)</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" id="MO4" position="float" orientation="portrait" xlink:href="10787_2021_850_Fig4_HTML.jpg"/></fig><fig id="Fig5" position="float" orientation="portrait"><label>Fig. 5</label><caption><p>Illustration of several COVID-19 vaccines and their mechanism (</p><p>modified from Dash et al. <xref ref-type="bibr" rid="CR21">2021</xref>)</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" id="MO5" position="float" orientation="portrait" xlink:href="10787_2021_850_Fig5_HTML.jpg"/></fig><fig id="Fig6" position="float" orientation="portrait"><label>Fig. 6</label><caption><p>Graphical representation of percentage efficacy of different COVID-19 vaccines</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" id="MO6" position="float" orientation="portrait" xlink:href="10787_2021_850_Fig6_HTML.jpg"/></fig></p><sec id="Sec9"><title>CoronaVac</title><p id="Par28">Sinovac vaccine denatured with aluminium hydroxide has progressed to phase 3 CT. It is fairly&#160;well-tolerated and immunogenic in healthy people (Zhang et al. <xref ref-type="bibr" rid="CR132">2020</xref>) as shown in Fig.&#160;<xref rid="Fig4" ref-type="fig">4</xref>.</p></sec><sec id="Sec10"><title>BNT162B1</title><p id="Par29">The nucleic acid vaccines include mRNA and DNA vaccines. These vaccines are translated into viral proteins after injection. S protein has been the most popular candidate among COVID-19 proteins. Because of their high potency and potential to degrade quickly, mRNA vaccines are prospective substitutes to other vaccines (Wang et al. <xref ref-type="bibr" rid="CR118">2020b</xref>). In phase 1/2 trials, BNT162B1 attacked the RBD of the S protein. The most vaccinators experienced mild to moderate systemic and local symptoms (Ewer et al. <xref ref-type="bibr" rid="CR27">2021</xref>). In phase 3 CT, a total of 43,548 people were randomly assigned, 21,720 were injected with BNT162b2 and 21,728 with placebo. In people 16 and older, a 2-dose treatment of it provided 95% efficacy (Polack et al. <xref ref-type="bibr" rid="CR86">2020</xref>).</p><p id="Par30">BioNTech (Pfizer) is the very first safe and effective vaccine which is authorized for emergency use in COVID-19, though, is not recommended by WHO in children below the age of 16&#160;years. Due to paucity of safety data in pregnant and lactating women, it can be vaccinated in these women depending on risk benefit ratio.</p></sec><sec id="Sec11"><title>mRNA1273</title><p id="Par31">The two-dose vaccine sequence did not produce adverse effects and could elicit neutralization and Th1-biased CD4&#8201;+&#8201;T-cell responses. The mode of action is shown in Fig.&#160;<xref rid="Fig4" ref-type="fig">4</xref>. According to a phase 1 trial, this vaccine was injected to a group and other group received placebo (15,210 members in each group) (Jackson et al. <xref ref-type="bibr" rid="CR46">2020</xref>). Its % efficacy is 94.1 (Fig.&#160;<xref rid="Fig6" ref-type="fig">6</xref>).</p></sec><sec id="Sec12"><title>Ad26COVS1</title><p id="Par32">It is a recombinant transgenic vaccine consisting of adenovirus type5 (rAd5) and 26 (rAd26) (Logunov et al. <xref ref-type="bibr" rid="CR69">2020</xref>) as shown in Fig.&#160;<xref rid="Fig4" ref-type="fig">4</xref>. There were 19,630 SARS-CoV-2&#8211;negative respondents were inoculated with Ad26COV2S1 and 19,691 individuals who received placebo. It exhibited 73.1 in severe and 81.7% efficacy (Fig.&#160;<xref rid="Fig6" ref-type="fig">6</xref>) in critical Covid-19, respectively (Sadoff et al. <xref ref-type="bibr" rid="CR93">2021</xref>). The Janssen (J and J) is recommended for immunization against COVID-19 by WHO for people of 18&#160;years and above. Pregnant and lactating women can be vaccinated with J&amp;J on the basis of risk benefit ratio. It will not recommend in hypersensitive individual or having history of allergy to component of vaccine.</p></sec><sec id="Sec13"><title>ChAdOx1 nCoV-19</title><p id="Par33">The effectiveness, protection, and immunogenicity of a chimp adeno (ChAd)-vectored vaccine framework encoding the S protein with codon optimization were observed. It was found to be stable, tolerable, and immunogenic in a phase 1 and 2 CTs. Furthermore, acetaminophen should be concomitantly used as it alleviates adverse reactions such as pain, fever, and muscle ache in post-vaccinated individual (Folegatti et al. <xref ref-type="bibr" rid="CR31">2020</xref>) as mentioned in Table <xref rid="Tab4" ref-type="table">4</xref>. The vaccine&#8217;s overall efficacy was 70.4% (Voysey et al. <xref ref-type="bibr" rid="CR114">2021</xref>) as mentioned in Fig.&#160;<xref rid="Fig6" ref-type="fig">6</xref>.</p><p id="Par34">AstraZeneca produced by Serum Institute of India and Republic of Korea is reviewed by European Medicine Agency (EMA) for safety, quality and efficacy and recommend its use for all people of 18&#160;years and more. Pregnant and lactating women can be vaccinated with AstraZeneca on the basis of risk benefit ratio. It will not recommend in hypersensitive individual or having history of allergic reactions to any component of vaccine.</p></sec><sec id="Sec14"><title>Sputnik V</title><p id="Par35">It is a vector vaccine that consists of rAd26 and rAd5 vaccine vectors, which is administered intramuscularly at 21-day intervals (Table <xref rid="Tab4" ref-type="table">4</xref>). In the virus, the dsDNA coding for the spike protein is preserved. Infected cells produce the spike protein that triggers an immune reaction (immunogenicity). In Moscow, a phase 3 RCT with placebo control was carried in 25 hospitals and polyclinics. It prevented infection in 91.6% (Fig.&#160;<xref rid="Fig6" ref-type="fig">6</xref>) with no significant adverse effects except rash and immune reaction. Three severe adverse effects were identified in the vaccine community among participants above the age of 60&#160;years included renal colic, deep vein thrombosis, and abscesses in the extremities as mentioned in Table <xref rid="Tab4" ref-type="table">4</xref> (Logunov et al. <xref ref-type="bibr" rid="CR70">2021</xref>). The mechanism of action of that vaccine is presented in Fig.&#160;<xref rid="Fig5" ref-type="fig">5</xref>.</p><p id="Par36">EpiVac corona and CoviVac are the two other Russian vaccines that are approved by Russian Government for emergency use. These two vaccines are now under large scale CTs. EpiVac is synthetic peptide antigen while CoviVac contains inactivated cold virus.</p></sec><sec id="Sec15"><title>BBIBP-CorV</title><p id="Par37">Inactivated or killed viruses can produce native antigenic epitopes (binding to T- and B-cell antibodies) present in a stable and conformational manner (Delrue et al. <xref ref-type="bibr" rid="CR24">2012</xref>). BBIBP-CorV is manufactured by Beijing Bio-Institute of Biological Products (BBIBP). In BBIBP-CorV vaccine, SARS-COV-2 is chemically inactive (with betapropiolactone), thus it cannot replicate but all of the protein is still intact. The Shangqiu City, China, conducted a phase 1/2 RCT of this vaccine in comparison to placebo control. The trial involved healthy individuals (aged 18&#8211;80&#160;years) in phase 1 and adult individuals (aged 18&#8211;59&#160;years) in phase 2. It is safe and well tolerated at all tested doses and presented 79% efficacy against Covid-19 (Xia et al. <xref ref-type="bibr" rid="CR123">2021</xref>).</p><p id="Par38">Sinopharm Vac (<italic toggle="yes">BBIBP-CorV</italic>) is still not authorized/reviewed by world&#8217;s chief drug regulatory authorities such as the FDA, European Medicine Agency (EMA) and the United Kingdom&#8217;s Medicines and Healthcare products. WHO has authorized its use for emergency in adults of above 18&#160;years on May 7, 2021. The commonly reported minor adverse effects of Sinopharma Vac in individuals aged 19&#8211;59 are fever, headache, allergy, pain, and swelling at injection site while serious includes nausea, facial nerve symptoms, clot formation, and acute disseminated encephalomyelitis. The WHO holds serious concerns over age gap for safety study of Chinese vaccine. There are various controversies about safety and efficacy of that Vac because of the lack of CT data regarding individuals above 60&#160;years of age. Aluminium hydroxide is used as adjuvant in Sinopharma Vac that strengthens the host&#8217;s immune system for incorporated vaccine (Baraniuk <xref ref-type="bibr" rid="CR5">2021</xref>; Crasto <xref ref-type="bibr" rid="CR18">2021</xref>).</p></sec><sec id="Sec16"><title>NVX-CoV2373</title><p id="Par39">Another strategy for vaccine production is to use protein S as a recombinant protein subunit. This approach may protect immunized cells in vitro, but it has the potential to produce a polarized immune response in humans. Novavax, a vaccine uses adjuvant Matrix-M<sup>&#8482;</sup> to improve immune response and has efficacy of 96% in COVID-19 patients under clinical trials phase 3 (Callaway and Mallapaty <xref ref-type="bibr" rid="CR9">2021</xref>). The most reported adverse effects among vaccine recipients were headache and muscle pain (Shinde et al. <xref ref-type="bibr" rid="CR101">2021</xref>).</p></sec><sec id="Sec17"><title>BBV152</title><p id="Par40">It is known as Covaxin manufactured by Bharat Biotech, India. It is an inactivated SARS-CoV-2 vaccine. At nine hospitals in India, a double-blind, RCT phase 2 was conducted to assess its immunogenicity and efficacy in healthy individuals (12&#8211;65&#160;years). It induced strong neutralizing antibody responses in the phase 1 trial, which were raised 3&#160;months later in all individuals. It showed enhanced reactogenicity, adaptive immunity and protection in phase 2 CT (Ella et al. <xref ref-type="bibr" rid="CR25">2021</xref>). It exhibits 81% efficacy against COVID-19 original strain in phase 3 CT (Fig.&#160;<xref rid="Fig6" ref-type="fig">6</xref>). The mechanism of action is presented in Fig.&#160;<xref rid="Fig5" ref-type="fig">5</xref>.</p></sec><sec id="Sec18"><title>Ad5-nCoV/CanSino</title><p id="Par41">It is another corona vaccine manufactured by CanSino Biologics, China. It has 65.7% efficacy. It is single shot vaccine with similar efficacy to other vector vaccines like J&amp;J, Gamaleya, AD26. It is recommended for people 18&#160;years of age and above (Sharma et al. <xref ref-type="bibr" rid="CR98">2020</xref>).</p></sec></sec></sec><sec id="Sec19"><title>Rare adverse effects of COVID-19 vaccines</title><p id="Par42">Janssen (J and J) was the very first, safe, and effective (older too) vaccine tool authorized for use by WHO and European Medicine Agency (EMA) in all countries, a step forward to combat COVID-19. On 13 Apr 2021, US regulatory agency temporarily restricted the use of J and J vaccine due to rarely reported adverse effects such as thrombosis and thrombocytopenia. The European regulators also reported thrombosis and thrombocytopenia with AstraZeneca vaccine in the same week. Blood clotting occurred mainly in veins of the brain and abdomen. Arteries are also affected in some cases, nevertheless the exact mechanism of thrombosis is ambiguous. Blood clotting is reported with AstraZeneca especially in women below 60&#160;years of age within 2&#160;weeks of vaccination. Heparin induced thrombocytopenia is also rarely reported adverse event among patients taking heparin (anticoagulants). HIT is also reported even in those individual who are not taking heparin&#160;(Greinacher et al. <xref ref-type="bibr" rid="CR36">2021</xref>).</p><p id="Par43">Schultz and coworker (<xref ref-type="bibr" rid="CR94">2021</xref>) conducted a study on healthcare workers (aged 32&#8211;54&#160;years) receiving AstraZeneca and reported venous thrombosis in 5 out of 130,000 vaccinated workers, who had not taken heparin. Moreover, the high titer of antibodies to platelet factor-4-polyanion complex was reported in those workers (Schultz et al. <xref ref-type="bibr" rid="CR94">2021</xref>). The regulators and researchers still recommend the use of AstraZeneca because the benefits of this vaccine outweigh the risks. The regulators and researchers still recommend the use of AstraZeneca vaccine because benefits outweigh the risks. Although several countries restrict its use in specific age groups, some countries hold its.</p><p id="Par44">Both are adenovirus vector vaccines encoding the corona spike protein in human cells. The human cell uses this DNA information for the synthesis of more spike protein that develops ultimately develops an immune reaction against it (Ledford <xref ref-type="bibr" rid="CR63">2021</xref>). There is a lack of HIT like reaction in recipients of mRNA vaccines. Another vaccine, Sputnik V containing a different adenovirus vector has also exhibited a rare blood clot formation reaction. Various factors influence the blood clot formation with different adenovirus vector containing vaccines (AstraZeneca, J and J, and Sputnik V) such as different viruses used, cells type in which they are produced, and number of spike protein they carry, the mode of their purity, and dose of administration (Baraniuk <xref ref-type="bibr" rid="CR5">2021</xref>).</p><p id="Par45">A study conducted on 64,503 COVID-19 patients showed that the prevalence of venous thromboembolism (VTE) was 14.7%, pulmonary embolism and deep vein thrombosis was 7.8 and 11.2%, respectively. The occurrence of VTE in COVID-19 hospitalized patients ranged from 0&#8211;69% (Tan et al. <xref ref-type="bibr" rid="CR109">2021</xref>). Although exact mechanism of arterial VTE in COVID-19 patients is still unclear yet the contribution of systemic and endothelial inflammation activating factors, vascular coagulopathy, fibrinogen, factor VIII action, hypoxemia, and antiphospholipid antibodies response are evident (Vickers et al. <xref ref-type="bibr" rid="CR112">2017</xref>).</p><p id="Par46">Virologists are currently working on the effect of various vaccines in vitro on vascular cells. The identification of trigger for that rare thrombosis effect is a key safety issue for the development of future vaccines. There is an immense need to sort out either we have to rely on adenovirus vaccines or turn towards mRNA vaccine development.</p><p id="Par47">The CDC has reported rare adverse effects such as pericarditis and myocarditis with mRNA COVID-19 vaccines (BioNTech and Moderna) in adolescent and young individuals but vaccine&#8217;s benefits outweigh the rarely reported potential risks and BioNTech is recommended for 12&#160;years and older (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.cdc.gov">https://www.cdc.gov</ext-link>).</p><p id="Par48">The additives and adjuvants used in COVID-19 vaccines may impart crucial role in causing rare and common adverse effects. Immunologists are unsure whether vectors, contamination in vectors or spike protein are responsible for antibody formation against platelet factor-4 in HIT. Allergic reactions occur mostly due to excipients/adjuvant rather than active moiety (Kounis et al. <xref ref-type="bibr" rid="CR200">2021</xref>). Allergic reactions either major or minor are encountered with vaccines likewise other medications. Anaphylactic reactions, often are life threating and rarely occurring allergic reactions, are occasionally instigated due to inert material called excipients used in vaccine formulation to heighten palatability, absorption, stability, solubility, etc. Polyethylene glycol is used as excipient in BioNTech and Moderna vaccines while Polysorbate-80 used in AstraZeneca and J and J COVID-19 vaccines. In a previous study, the prevalence of allergic reactions was reported to be 1.31 out of a million vaccinated individuals, age and sex were equally contributing factors but females were appeared to be more sensitive in this regard (Kounis et al. <xref ref-type="bibr" rid="CR200">2021</xref>).</p><p id="Par49">Adjuvants have been using in vaccines formulation for a long time, Aluminum salt based adjuvants (Alum) are the first recommended adjuvants for human use vaccines because of their consolidating effect on the immune response and good safety record (Liang et al. <xref ref-type="bibr" rid="CR66">2020</xref>). Adjuvants are also responsible for post vaccination adverse events. Aluminium hydroxide used as adjuvant in SARS coronavirus vaccine comprising of inactivated (by formalin or beta propiolactone) virus exhibited lung immunopathology in a previous study carried on mice&#160;(Tseng et al. <xref ref-type="bibr" rid="CR110">2012</xref>). Al salts also exhibited neurotoxicity and led to autoimmune reactions (Shaw et al. <xref ref-type="bibr" rid="CR99">2014</xref>; Danielsson and Eriksson <xref ref-type="bibr" rid="CR20">2021</xref>; Shoenfeld and Agmon <xref ref-type="bibr" rid="CR102">2011</xref>).</p></sec></sec><sec id="Sec20"><title>Conclusion</title><p id="Par50">Allopathic medications cause acute toxicity in patients, which reduces the benefits of antiviral drugs and that risk exacerbates in patients with underlying heart or liver diseases. This toxicity risk prompts patient noncompliance and switch towards the alternative medicines that have lower side effects as compared to pharmacological drugs. Despite immense efforts and studies in the field of drug repurposing, significant roadblocks remain in the way of widespread use of repurposed medications, including problems with clinical dosage, safety, and delivery capabilities. Due to differences in choice of alternative medicines and lack of standardized data of the investigated formulations, it is currently difficult to draw information from the past studies. Nonetheless, there is inadequate evidence of significant antiviral effects unique to the SARS-CoV-2 virus. To determine their role in COVID-19 treatment, further research is needed to evaluate the detail mechanism regarding anti-inflammatory and immunomodulatory effects, and also the safety and quality of herbal medicines should be studied in COVID-19 patients/healthy individuals. Furthermore, there is an immense need to sort out more vaccines against COVID-19 with 98&#8211;99% efficacy that should be cheap and safe in use. The clinical trials of available vaccines should be conducted on a large group of participants, including pregnant and lactating females as well as children of different age groups as there is no single COVID-19 vaccine for maternal and children below 12&#160;years of age. The safety profile of vaccine is crucial in the success of any vaccination program. Vaccine pharmacovigilance is playing a significant role in finding out a safe antiCOVID-19 vaccine that had developed. There is massive demand of robust vigilance system to find and resolve untoward effects linked to anti-COVID-19 vaccine. Due to complicated safety and efficacy concerns, CDA does not recommend one anti-COVID-19 vaccine over the other. Last but not the least, precautionary measures such as wearing mask and social distancing are better than getting infected. To date, there is no single curative treatment for this morbid and fatal virus.</p></sec></body><back><fn-group><fn><p><bold>Publisher's Note</bold></p><p>Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.</p></fn></fn-group><ack><title>Acknowledgements</title><p>This study is not funded by any government and private agency.</p></ack><notes notes-type="author-contribution"><title>Author contributions</title><p>AS and MFA planned and designed the study. All authors contributed to data collection. AS and MFA wrote the manuscript. AS, MFA and MMAD critically reviewed and revised the manuscript. All authors read and approved the manuscript.</p></notes><notes><title>Declarations</title><notes id="FPar1" notes-type="COI-statement"><title>Conflict of interest</title><p id="Par51">Authors declare no conflict of interest.</p></notes></notes><ref-list id="Bib1"><title>References</title><ref id="CR1"><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Adhikari</surname><given-names>B</given-names></name><name name-style="western"><surname>Marasini</surname><given-names>BP</given-names></name><name name-style="western"><surname>Rayamajhee</surname><given-names>B</given-names></name><etal/></person-group><article-title>Potential roles of medicinal plants for the treatment of viral diseases focusing on COVID-19: a review</article-title><source>Phytother Res</source><year>2021</year><volume>35</volume><fpage>1298</fpage><lpage>1312</lpage><pub-id pub-id-type="doi">10.1002/ptr.6893</pub-id><pub-id pub-id-type="pmid">33037698</pub-id><pub-id pub-id-type="pmcid">PMC7675695</pub-id></element-citation></ref><ref id="CR2"><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Al Hamdany</surname><given-names>A</given-names></name><name name-style="western"><surname>Al-Khatib</surname><given-names>A</given-names></name><name name-style="western"><surname>Al-Sadi</surname><given-names>H</given-names></name></person-group><article-title>An overview of the beneficial effects of qurecitin on bone</article-title><source>Int Med J</source><year>2019</year><volume>26</volume><issue>2</issue><fpage>142</fpage><lpage>145</lpage></element-citation></ref><ref id="CR3"><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Baden</surname><given-names>LR</given-names></name><name name-style="western"><surname>El Sahly</surname><given-names>HM</given-names></name><name name-style="western"><surname>Essink</surname><given-names>B</given-names></name><etal/></person-group><article-title>Efficacy and safety of the mRNA-1273 SARS-CoV-2 vaccine</article-title><source>N Engl J Med</source><year>2021</year><volume>384</volume><fpage>403</fpage><lpage>416</lpage><pub-id pub-id-type="doi">10.1056/NEJMoa2035389</pub-id><pub-id pub-id-type="pmid">33378609</pub-id><pub-id pub-id-type="pmcid">PMC7787219</pub-id></element-citation></ref><ref id="CR4"><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Baig</surname><given-names>AM</given-names></name><name name-style="western"><surname>Khaleeq</surname><given-names>A</given-names></name><name name-style="western"><surname>Ali</surname><given-names>U</given-names></name><etal/></person-group><article-title>Evidence of the COVID-19 virus targeting the CNS: tissue distribution, host&#8211;virus interaction, and proposed neurotropic mechanisms</article-title><source>ACS Chem Neurosci</source><year>2020</year><volume>11</volume><fpage>995</fpage><lpage>998</lpage><pub-id pub-id-type="doi">10.1021/acschemneuro.0c00122</pub-id><pub-id pub-id-type="pmid">32167747</pub-id></element-citation></ref><ref id="CR5"><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Baraniuk</surname><given-names>C</given-names></name></person-group><article-title>Covid-19: What do we know about Sputnik V and other Russian vaccines?</article-title><source>BMJ</source><year>2021</year><volume>372</volume><fpage>n743</fpage><pub-id pub-id-type="doi">10.1136/bmj.n743</pub-id><pub-id pub-id-type="pmid">33741559</pub-id></element-citation></ref><ref id="CR6"><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Beck</surname><given-names>BR</given-names></name><name name-style="western"><surname>Shin</surname><given-names>B</given-names></name><name name-style="western"><surname>Choi</surname><given-names>Y</given-names></name><etal/></person-group><article-title>Predicting commercially available antiviral drugs that may act on the novel coronavirus (SARS-CoV-2) through a drug-target interaction deep learning model</article-title><source>Comput Struct Biotechnol J</source><year>2020</year><volume>18</volume><fpage>784</fpage><lpage>790</lpage><pub-id pub-id-type="doi">10.1016/j.csbj.2020.03.025</pub-id><pub-id pub-id-type="pmid">32280433</pub-id><pub-id pub-id-type="pmcid">PMC7118541</pub-id></element-citation></ref><ref id="CR7"><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Biggioggero</surname><given-names>M</given-names></name><name name-style="western"><surname>Crotti</surname><given-names>C</given-names></name><name name-style="western"><surname>Becciolini</surname><given-names>A</given-names></name><etal/></person-group><article-title>Tocilizumab in the treatment of rheumatoid arthritis: an evidence-based review and patient selection</article-title><source>Drug Des Dev Ther</source><year>2019</year><volume>13</volume><fpage>57</fpage><pub-id pub-id-type="doi">10.2147/DDDT.S150580</pub-id><pub-id pub-id-type="pmcid">PMC6304084</pub-id><pub-id pub-id-type="pmid">30587928</pub-id></element-citation></ref><ref id="CR9"><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Callaway</surname><given-names>E</given-names></name><name name-style="western"><surname>Mallapaty</surname><given-names>S</given-names></name></person-group><article-title>Novavax Covid vaccine protects people against variants</article-title><source>Nature</source><year>2021</year><volume>590</volume><fpage>17</fpage><pub-id pub-id-type="doi">10.1038/d41586-021-00268-9</pub-id><pub-id pub-id-type="pmid">33510489</pub-id></element-citation></ref><ref id="CR10"><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Chang</surname><given-names>JHM</given-names></name><name name-style="western"><surname>Lin</surname><given-names>CH</given-names></name><name name-style="western"><surname>Shibu</surname><given-names>MA</given-names></name><etal/></person-group><article-title>Cryptotanshinone (Dsh-003) from Salvia miltiorrhiza Bunge inhibits prostaglandin E2-induced survival and invasion effects in HA22T hepatocellular carcinoma cells</article-title><source>Environ Toxicol</source><year>2018</year><volume>33</volume><fpage>1254</fpage><lpage>1260</lpage><pub-id pub-id-type="doi">10.1002/tox.22633</pub-id><pub-id pub-id-type="pmid">30208247</pub-id></element-citation></ref><ref id="CR12"><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Chen</surname><given-names>H-S</given-names></name><name name-style="western"><surname>Qi</surname><given-names>S-H</given-names></name><name name-style="western"><surname>Shen</surname><given-names>J-G</given-names></name></person-group><article-title>One-compound-multi-target: combination prospect of natural compounds with thrombolytic therapy in acute ischemic stroke</article-title><source>Curr Neuropharmacol</source><year>2017</year><volume>15</volume><fpage>134</fpage><lpage>156</lpage><pub-id pub-id-type="doi">10.2174/1570159X14666160620102055</pub-id><pub-id pub-id-type="pmid">27334020</pub-id><pub-id pub-id-type="pmcid">PMC5327453</pub-id></element-citation></ref><ref id="CR13"><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Chen</surname><given-names>T</given-names></name><name name-style="western"><surname>Fei</surname><given-names>C-Y</given-names></name><name name-style="western"><surname>Chen</surname><given-names>Y-P</given-names></name><etal/></person-group><article-title>Synergistic inhibition of SARS-CoV-2 replication using Disulfiram/Eebselen and Remdesivir</article-title><source>ACS Pharmacol Trans Sci</source><year>2021</year><volume>4</volume><fpage>898</fpage><lpage>907</lpage><pub-id pub-id-type="doi">10.1021/acsptsci.1c00022</pub-id><pub-id pub-id-type="pmcid">PMC8009100</pub-id><pub-id pub-id-type="pmid">33855277</pub-id></element-citation></ref><ref id="CR14"><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Cione</surname><given-names>E</given-names></name><name name-style="western"><surname>La Torre</surname><given-names>C</given-names></name><name name-style="western"><surname>Cannataro</surname><given-names>R</given-names></name><etal/></person-group><article-title>Quercetin, epigallocatechin gallate, curcumin, and resveratrol: from dietary sources to human microRNA modulation</article-title><source>Molecules</source><year>2020</year><volume>25</volume><fpage>63</fpage><pub-id pub-id-type="doi">10.3390/molecules25010063</pub-id><pub-id pub-id-type="pmcid">PMC6983040</pub-id><pub-id pub-id-type="pmid">31878082</pub-id></element-citation></ref><ref id="CR15"><element-citation publication-type="journal"><person-group person-group-type="author"><collab>Consortium WST</collab></person-group><article-title>Repurposed antiviral drugs for COVID-19&#8212;interim WHO SOLIDARITY trial results</article-title><source>N Engl J Med</source><year>2021</year><volume>384</volume><fpage>497</fpage><lpage>511</lpage><pub-id pub-id-type="doi">10.1056/NEJMoa2023184</pub-id><pub-id pub-id-type="pmid">33264556</pub-id><pub-id pub-id-type="pmcid">PMC7727327</pub-id></element-citation></ref><ref id="CR16"><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Corbett</surname><given-names>KS</given-names></name><name name-style="western"><surname>Flynn</surname><given-names>B</given-names></name><name name-style="western"><surname>Foulds</surname><given-names>KE</given-names></name><etal/></person-group><article-title>Evaluation of the mRNA-1273 vaccine against SARS-CoV-2 in nonhuman primates</article-title><source>N Engl J Med</source><year>2020</year><volume>383</volume><fpage>1544</fpage><lpage>1555</lpage><pub-id pub-id-type="doi">10.1056/NEJMoa2024671</pub-id><pub-id pub-id-type="pmid">32722908</pub-id><pub-id pub-id-type="pmcid">PMC7449230</pub-id></element-citation></ref><ref id="CR18"><mixed-citation publication-type="other">Crasto A M (2021). BBIBP-CorV, Sinopharm COVID-19 vaccine. new drug approvals. <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://newdrugapprovals.org/2021/03/23/bbibp-corv-sinopharm-covid-19-vaccine/">https://newdrugapprovals.org/2021/03/23/bbibp-corv-sinopharm-covid-19-vaccine/</ext-link>. Accessed on Apr, 12, 2021.</mixed-citation></ref><ref id="CR19"><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>da Silva</surname><given-names>AA</given-names></name><name name-style="western"><surname>Wiedemann</surname><given-names>LSM</given-names></name><name name-style="western"><surname>Veiga-Junior</surname><given-names>VF</given-names></name></person-group><article-title>Natural product&#8217;s role against COVID-19</article-title><source>RSC Adv</source><year>2020</year><volume>10</volume><fpage>23379</fpage><lpage>23393</lpage><pub-id pub-id-type="doi">10.1039/D0RA03774E</pub-id><pub-id pub-id-type="pmid">35693131</pub-id><pub-id pub-id-type="pmcid">PMC9122563</pub-id></element-citation></ref><ref id="CR20"><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Danielsson</surname><given-names>R</given-names></name><name name-style="western"><surname>Eriksson</surname><given-names>H</given-names></name></person-group><article-title>Aluminium adjuvants in vaccines&#8211;A way to modulate the immune response</article-title><source>Semin Cell Dev Biol</source><year>2021</year><volume>115</volume><fpage>3</fpage><lpage>9</lpage><pub-id pub-id-type="doi">10.1016/j.semcdb.2020.12.008</pub-id><pub-id pub-id-type="pmid">33423930</pub-id></element-citation></ref><ref id="CR21"><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Dash</surname><given-names>P</given-names></name><name name-style="western"><surname>Mohapatra</surname><given-names>S</given-names></name><name name-style="western"><surname>Ghosh</surname><given-names>S</given-names></name><etal/></person-group><article-title>A scoping insight on potential prophylactics, vaccines and therapeutic weaponry for the ongoing novel Coronavirus (COVID-19) pandemic-a comprehensive review</article-title><source>Front Pharmacol</source><year>2021</year><volume>11</volume><fpage>2471</fpage><pub-id pub-id-type="doi">10.3389/fphar.2020.590154</pub-id><pub-id pub-id-type="pmcid">PMC8015872</pub-id><pub-id pub-id-type="pmid">33815095</pub-id></element-citation></ref><ref id="CR22"><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Daskaya-Dikmen</surname><given-names>C</given-names></name><name name-style="western"><surname>Yucetepe</surname><given-names>A</given-names></name><name name-style="western"><surname>Karbancioglu-Guler</surname><given-names>F</given-names></name><etal/></person-group><article-title>Angiotensin-I-converting enzyme (ACE)-inhibitory peptides from plants</article-title><source>Nutrients</source><year>2017</year><volume>9</volume><fpage>316</fpage><pub-id pub-id-type="doi">10.3390/nu9040316</pub-id><pub-id pub-id-type="pmid">28333109</pub-id><pub-id pub-id-type="pmcid">PMC5409655</pub-id></element-citation></ref><ref id="CR23"><mixed-citation publication-type="other">David J Cennimo M, FAAP, FACP, AAHIVS. (2020) What is the role of the IL-6 inhibitor tocilizumab (Actemra) in the treatment of coronavirus disease 2019 (COVID-19)? Available at: <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.medscape.com/answers/2500114-197457/what-is-the-role-of-the-il-6-inhibitor-tocilizumab-actemra-in-the-treatment-of-coronavirus-disease-2019-covid-19">https://www.medscape.com/answers/2500114-197457/what-is-the-role-of-the-il-6-inhibitor-tocilizumab-actemra-in-the-treatment-of-coronavirus-disease-2019-covid-19</ext-link>.</mixed-citation></ref><ref id="CR24"><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Delrue</surname><given-names>I</given-names></name><name name-style="western"><surname>Verzele</surname><given-names>D</given-names></name><name name-style="western"><surname>Madder</surname><given-names>A</given-names></name><etal/></person-group><article-title>Inactivated virus vaccines from chemistry to prophylaxis: merits, risks and challenges</article-title><source>Expert Rev Vaccines</source><year>2012</year><volume>11</volume><fpage>695</fpage><lpage>719</lpage><pub-id pub-id-type="doi">10.1586/erv.12.38</pub-id><pub-id pub-id-type="pmid">22873127</pub-id></element-citation></ref><ref id="CR25"><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ella</surname><given-names>R</given-names></name><name name-style="western"><surname>Vadrevu</surname><given-names>KM</given-names></name><name name-style="western"><surname>Jogdand</surname><given-names>H</given-names></name><etal/></person-group><article-title>Safety and immunogenicity of an inactivated SARS-CoV-2 vaccine, BBV152: a double-blind, randomised, phase 1 trial</article-title><source>Lancet Infect Dis</source><year>2021</year><volume>21</volume><fpage>637</fpage><lpage>646</lpage><pub-id pub-id-type="doi">10.1016/S1473-3099(20)30942-7</pub-id><pub-id pub-id-type="pmid">33485468</pub-id><pub-id pub-id-type="pmcid">PMC7825810</pub-id></element-citation></ref><ref id="CR26"><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Enmozhi</surname><given-names>SK</given-names></name><name name-style="western"><surname>Raja</surname><given-names>K</given-names></name><name name-style="western"><surname>Sebastine</surname><given-names>I</given-names></name><etal/></person-group><article-title>Andrographolide as a potential inhibitor of SARS-CoV-2 main protease: an in silico approach</article-title><source>J Biomol Struct Dyna</source><year>2021</year><volume>39</volume><issue>9</issue><fpage>3092</fpage><lpage>3098</lpage><pub-id pub-id-type="doi" assigning-authority="pmc">10.1080/07391102.2020.1760136</pub-id><pub-id pub-id-type="pmcid">PMC7212536</pub-id><pub-id pub-id-type="pmid">32329419</pub-id></element-citation></ref><ref id="CR27"><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ewer</surname><given-names>KJ</given-names></name><name name-style="western"><surname>Barrett</surname><given-names>JR</given-names></name><name name-style="western"><surname>Belij-Rammerstorfer</surname><given-names>S</given-names></name><etal/></person-group><article-title>T cell and antibody responses induced by a single dose of ChAdOx1 nCoV-19 (AZD1222) vaccine in a phase 1/2 clinical trial</article-title><source>Nat Med</source><year>2021</year><volume>27</volume><fpage>270</fpage><lpage>278</lpage><pub-id pub-id-type="doi">10.1038/s41591-020-01194-5</pub-id><pub-id pub-id-type="pmid">33335323</pub-id></element-citation></ref><ref id="CR28"><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Fasuan</surname><given-names>TO</given-names></name><name name-style="western"><surname>Gbadamosi</surname><given-names>SO</given-names></name><name name-style="western"><surname>Akanbi</surname><given-names>CT</given-names></name></person-group><article-title>Modification of amaranth (Amaranthus viridis) starch, identification of functional groups, and its potentials as fat replacer</article-title><source>J Food Biochem</source><year>2018</year><volume>42</volume><fpage>e12537</fpage><pub-id pub-id-type="doi">10.1111/jfbc.12537</pub-id></element-citation></ref><ref id="CR29"><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>FehrPSMBickertson</surname><given-names>AHJE</given-names></name><etal/></person-group><article-title>An overview of their replication and pathogenesis; section 2 genomic organization</article-title><source>Methods Mol Biol Springer</source><year>2015</year><volume>1282</volume><fpage>1</fpage><lpage>23</lpage><pub-id pub-id-type="doi">10.1007/978-1-4939-2438-7_1</pub-id></element-citation></ref><ref id="CR30"><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Felsenstein</surname><given-names>S</given-names></name><name name-style="western"><surname>Herbert</surname><given-names>JA</given-names></name><name name-style="western"><surname>McNamara</surname><given-names>PS</given-names></name><etal/></person-group><article-title>COVID-19: immunology and treatment options</article-title><source>Clin Immunol</source><year>2020</year><volume>215</volume><fpage>108448</fpage><pub-id pub-id-type="doi">10.1016/j.clim.2020.108448</pub-id><pub-id pub-id-type="pmid">32353634</pub-id><pub-id pub-id-type="pmcid">PMC7185015</pub-id></element-citation></ref><ref id="CR31"><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Folegatti</surname><given-names>PM</given-names></name><name name-style="western"><surname>Ewer</surname><given-names>KJ</given-names></name><name name-style="western"><surname>Aley</surname><given-names>PK</given-names></name><etal/></person-group><article-title>Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1/2, single-blind, randomised controlled trial</article-title><source>Lancet</source><year>2020</year><volume>396</volume><fpage>467</fpage><lpage>478</lpage><pub-id pub-id-type="doi">10.1016/S0140-6736(20)31604-4</pub-id><pub-id pub-id-type="pmid">32702298</pub-id><pub-id pub-id-type="pmcid">PMC7445431</pub-id></element-citation></ref><ref id="CR32"><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Forni</surname><given-names>G</given-names></name><name name-style="western"><surname>Mantovani</surname><given-names>A</given-names></name></person-group><article-title>COVID-19 vaccines: where we stand and challenges ahead</article-title><source>Cell Death Differ</source><year>2021</year><volume>28</volume><fpage>626</fpage><lpage>639</lpage><pub-id pub-id-type="doi">10.1038/s41418-020-00720-9</pub-id><pub-id pub-id-type="pmid">33479399</pub-id><pub-id pub-id-type="pmcid">PMC7818063</pub-id></element-citation></ref><ref id="CR33"><mixed-citation publication-type="other">Fotovvat M, Radjabian T and Saboora A (2017) Tanshinone compositions in wild growing salvia Xantocheilla boiss of Iran. 6th National Congress on Medicinal Plants. 6th National Congress on Medicinal Plants.</mixed-citation></ref><ref id="CR34"><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Gao</surname><given-names>Q</given-names></name><name name-style="western"><surname>Bao</surname><given-names>L</given-names></name><name name-style="western"><surname>Mao</surname><given-names>H</given-names></name><etal/></person-group><article-title>Development of an inactivated vaccine candidate for SARS-CoV-2</article-title><source>Science</source><year>2020</year><volume>369</volume><fpage>77</fpage><lpage>81</lpage><pub-id pub-id-type="doi">10.1126/science.abc1932</pub-id><pub-id pub-id-type="pmid">32376603</pub-id><pub-id pub-id-type="pmcid">PMC7202686</pub-id></element-citation></ref><ref id="CR35"><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Goodarzi</surname><given-names>S</given-names></name><name name-style="western"><surname>Tabatabaei</surname><given-names>MJ</given-names></name><name name-style="western"><surname>Mohammad Jafari</surname><given-names>R</given-names></name><etal/></person-group><article-title>Cuminum cyminum fruits as source of luteolin-7-O-glucoside, potent cytotoxic flavonoid against breast cancer cell lines</article-title><source>Nat Prod Res</source><year>2020</year><volume>34</volume><fpage>1602</fpage><lpage>1606</lpage><pub-id pub-id-type="doi">10.1080/14786419.2018.1519824</pub-id><pub-id pub-id-type="pmid">30580606</pub-id></element-citation></ref><ref id="CR36"><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Greinacher</surname><given-names>A</given-names></name><name name-style="western"><surname>Thiele</surname><given-names>T</given-names></name><name name-style="western"><surname>Warkentin</surname><given-names>TE</given-names></name><name name-style="western"><surname>Weisser</surname><given-names>K</given-names></name><etal/></person-group><article-title>Thrombotic thrombocytopenia after ChAdOx1 nCov-19 vaccination</article-title><source>New Engl J Med</source><year>2021</year><volume>384</volume><fpage>2092</fpage><lpage>2101</lpage><pub-id pub-id-type="doi">10.1056/NEJMoa2104840</pub-id><pub-id pub-id-type="pmid">33835769</pub-id><pub-id pub-id-type="pmcid">PMC8095372</pub-id></element-citation></ref><ref id="CR37"><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Harrison</surname><given-names>C</given-names></name></person-group><article-title>Coronavirus puts drug repurposing on the fast track</article-title><source>Nat Biotechnol</source><year>2020</year><volume>38</volume><fpage>379</fpage><lpage>381</lpage><pub-id pub-id-type="doi">10.1038/d41587-020-00003-1</pub-id><pub-id pub-id-type="pmid">32205870</pub-id></element-citation></ref><ref id="CR38"><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hasan</surname><given-names>M</given-names></name><name name-style="western"><surname>Bae</surname><given-names>H</given-names></name></person-group><article-title>An overview of stress-induced resveratrol synthesis in grapes: perspectives for resveratrol-enriched grape products</article-title><source>Molecules</source><year>2017</year><volume>22</volume><fpage>294</fpage><pub-id pub-id-type="doi">10.3390/molecules22020294</pub-id><pub-id pub-id-type="pmid">28216605</pub-id><pub-id pub-id-type="pmcid">PMC6155908</pub-id></element-citation></ref><ref id="CR39"><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>He</surname><given-names>LL</given-names></name><name name-style="western"><surname>Gong</surname><given-names>PY</given-names></name><name name-style="western"><surname>Feng</surname><given-names>Y</given-names></name><etal/></person-group><article-title>Analysis on application of Chinese materia medica in treatment of COVID-19 by suppressing cytokine storm</article-title><source>Chin Tradit Herbal Drugs</source><year>2020</year><volume>6</volume><issue>51</issue><fpage>1375</fpage><lpage>1385</lpage></element-citation></ref><ref id="CR40"><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hirai</surname><given-names>M</given-names></name><name name-style="western"><surname>Matsuoka</surname><given-names>H</given-names></name><name name-style="western"><surname>Syafruddin</surname><given-names>D</given-names></name><etal/></person-group><article-title>Publications from Juntendo University Graduate School of Medicine, 2015 [6/6]</article-title><source>Health</source><year>2015</year><volume>43</volume><fpage>53</fpage><lpage>61</lpage></element-citation></ref><ref id="CR41"><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hoffmann</surname><given-names>M</given-names></name><name name-style="western"><surname>Kleine-Weber</surname><given-names>H</given-names></name><name name-style="western"><surname>Schroeder</surname><given-names>S</given-names></name><etal/></person-group><article-title>SARS-CoV-2 cell entry depends on ACE2 and TMPRSS2 and is blocked by a clinically proven protease inhibitor</article-title><source>Cell</source><year>2020</year><volume>181</volume><fpage>271</fpage><lpage>280.e8</lpage><pub-id pub-id-type="doi">10.1016/j.cell.2020.02.052</pub-id><pub-id pub-id-type="pmid">32142651</pub-id><pub-id pub-id-type="pmcid">PMC7102627</pub-id></element-citation></ref><ref id="CR42"><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hordyjewska</surname><given-names>A</given-names></name><name name-style="western"><surname>Ostapiuk</surname><given-names>A</given-names></name><name name-style="western"><surname>Horecka</surname><given-names>A</given-names></name><etal/></person-group><article-title>Betulin and betulinic acid: triterpenoids derivatives with a powerful biological potential</article-title><source>Phytochem Rev</source><year>2019</year><volume>18</volume><fpage>929</fpage><lpage>951</lpage><pub-id pub-id-type="doi">10.1007/s11101-019-09623-1</pub-id></element-citation></ref><ref id="CR43"><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hu</surname><given-names>G</given-names></name><name name-style="western"><surname>Peng</surname><given-names>C</given-names></name><name name-style="western"><surname>Xie</surname><given-names>X</given-names></name><etal/></person-group><article-title>Availability, pharmaceutics, security, pharmacokinetics, and pharmacological activities of patchouli alcohol</article-title><source>Evid Based Complement Alter Med</source><year>2017</year><volume>2017</volume><fpage>1</fpage><lpage>7</lpage><pub-id pub-id-type="doi" assigning-authority="pmc">10.1155/2017/4850612</pub-id><pub-id pub-id-type="pmcid">PMC5379095</pub-id><pub-id pub-id-type="pmid">28421121</pub-id></element-citation></ref><ref id="CR44"><mixed-citation publication-type="other">Huang F, Li Y, Leung EL-H et al (2020) A review of therapeutic agents and Chinese herbal medicines against SARS-COV-2 (COVID-19). Pharmacol Res: 104929.<pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.phrs.2020.104929</pub-id><pub-id pub-id-type="pmcid">PMC7237953</pub-id><pub-id pub-id-type="pmid">32442720</pub-id></mixed-citation></ref><ref id="CR45"><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hulswit</surname><given-names>RJ</given-names></name><name name-style="western"><surname>Lang</surname><given-names>Y</given-names></name><name name-style="western"><surname>Bakkers</surname><given-names>MJ</given-names></name><etal/></person-group><article-title>Human coronaviruses OC43 and HKU1 bind to 9-O-acetylated sialic acids via a conserved receptor-binding site in spike protein domain A</article-title><source>Proc Natl Acad Sci</source><year>2019</year><volume>116</volume><fpage>2681</fpage><lpage>2690</lpage><pub-id pub-id-type="doi">10.1073/pnas.1809667116</pub-id><pub-id pub-id-type="pmid">30679277</pub-id><pub-id pub-id-type="pmcid">PMC6377473</pub-id></element-citation></ref><ref id="CR46"><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Jackson</surname><given-names>LA</given-names></name><name name-style="western"><surname>Anderson</surname><given-names>EJ</given-names></name><name name-style="western"><surname>Rouphael</surname><given-names>NG</given-names></name><etal/></person-group><article-title>An mRNA vaccine against SARS-CoV-2&#8212;preliminary report</article-title><source>New Engl J Med</source><year>2020</year><volume>383</volume><issue>20</issue><fpage>1920</fpage><lpage>1931</lpage><pub-id pub-id-type="doi">10.1056/NEJMoa2022483</pub-id><pub-id pub-id-type="pmid">32663912</pub-id><pub-id pub-id-type="pmcid">PMC7377258</pub-id></element-citation></ref><ref id="CR47"><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Jia</surname><given-names>HP</given-names></name><name name-style="western"><surname>Look</surname><given-names>DC</given-names></name><name name-style="western"><surname>Shi</surname><given-names>L</given-names></name><etal/></person-group><article-title>ACE2 receptor expression and severe acute respiratory syndrome coronavirus infection depend on differentiation of human airway epithelia</article-title><source>J Virol</source><year>2005</year><volume>79</volume><fpage>14614</fpage><lpage>14621</lpage><pub-id pub-id-type="doi">10.1128/JVI.79.23.14614-14621.2005</pub-id><pub-id pub-id-type="pmid">16282461</pub-id><pub-id pub-id-type="pmcid">PMC1287568</pub-id></element-citation></ref><ref id="CR48"><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Jiang</surname><given-names>G</given-names></name><name name-style="western"><surname>Liu</surname><given-names>J</given-names></name><name name-style="western"><surname>Ren</surname><given-names>B</given-names></name><etal/></person-group><article-title>Anti-tumor and chemosensitization effects of Cryptotanshinone extracted from Salvia miltiorrhiza Bge. on ovarian cancer cells in vitro</article-title><source>J Ethnopharmacol</source><year>2017</year><volume>205</volume><fpage>33</fpage><lpage>40</lpage><pub-id pub-id-type="doi">10.1016/j.jep.2017.04.026</pub-id><pub-id pub-id-type="pmid">28456578</pub-id></element-citation></ref><ref id="CR49"><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Jiang</surname><given-names>Y</given-names></name><name name-style="western"><surname>Yin</surname><given-names>W</given-names></name><name name-style="western"><surname>Xu</surname><given-names>HE</given-names></name></person-group><article-title>RNA-dependent RNA polymerase: structure, mechanism, and drug discovery for COVID-19</article-title><source>Biochem Biophys Res Commun</source><year>2021</year><volume>538</volume><fpage>47</fpage><lpage>53</lpage><pub-id pub-id-type="doi">10.1016/j.bbrc.2020.08.116</pub-id><pub-id pub-id-type="pmid">32943188</pub-id><pub-id pub-id-type="pmcid">PMC7473028</pub-id></element-citation></ref><ref id="CR50"><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Jin</surname><given-names>C-C</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>J-L</given-names></name><name name-style="western"><surname>Song</surname><given-names>H</given-names></name><etal/></person-group><article-title>Boosting the biosynthesis of betulinic acid and related triterpenoids in Yarrowia lipolytica via multimodular metabolic engineering</article-title><source>Microb Cell Fact</source><year>2019</year><volume>18</volume><fpage>1</fpage><lpage>18</lpage><pub-id pub-id-type="doi">10.1186/s12934-019-1127-8</pub-id><pub-id pub-id-type="pmid">31053076</pub-id><pub-id pub-id-type="pmcid">PMC6498500</pub-id></element-citation></ref><ref id="CR51"><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Jin</surname><given-names>Z</given-names></name><name name-style="western"><surname>Du</surname><given-names>X</given-names></name><name name-style="western"><surname>Xu</surname><given-names>Y</given-names></name><etal/></person-group><article-title>Structure of M pro from SARS-CoV-2 and discovery of its inhibitors</article-title><source>Nature</source><year>2020</year><volume>582</volume><fpage>289</fpage><lpage>293</lpage><pub-id pub-id-type="doi">10.1038/s41586-020-2223-y</pub-id><pub-id pub-id-type="pmid">32272481</pub-id></element-citation></ref><ref id="CR52"><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Joshi</surname><given-names>RS</given-names></name><name name-style="western"><surname>Jagdale</surname><given-names>SS</given-names></name><name name-style="western"><surname>Bansode</surname><given-names>SB</given-names></name><etal/></person-group><article-title>Discovery of potential multi-target-directed ligands by targeting host-specific SARS-CoV-2 structurally conserved main protease</article-title><source>J Biomol Struct Dynam</source><year>2021</year><volume>39</volume><issue>9</issue><fpage>3099</fpage><lpage>3114</lpage><pub-id pub-id-type="doi" assigning-authority="pmc">10.1080/07391102.2020.1760137</pub-id><pub-id pub-id-type="pmcid">PMC7212545</pub-id><pub-id pub-id-type="pmid">32329408</pub-id></element-citation></ref><ref id="CR53"><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Karuppaiya</surname><given-names>P</given-names></name><name name-style="western"><surname>Tsay</surname><given-names>HS</given-names></name></person-group><article-title>Enhanced production of podophyllotoxin, kaempferol, and quercetin from callus culture of Dysosma pleiantha (Hance) Woodson: an endangered medicinal plant</article-title><source>Biotechnol Appl Biochem</source><year>2020</year><volume>67</volume><fpage>95</fpage><lpage>104</lpage><pub-id pub-id-type="doi">10.1002/bab.1810</pub-id><pub-id pub-id-type="pmid">31489710</pub-id></element-citation></ref><ref id="CR54"><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Keech</surname><given-names>C</given-names></name><name name-style="western"><surname>Albert</surname><given-names>G</given-names></name><name name-style="western"><surname>Cho</surname><given-names>I</given-names></name><etal/></person-group><article-title>Phase 1&#8211;2 trial of a SARS-CoV-2 recombinant spike protein nanoparticle vaccine</article-title><source>N Engl J Med</source><year>2020</year><volume>383</volume><fpage>2320</fpage><lpage>2332</lpage><pub-id pub-id-type="doi">10.1056/NEJMoa2026920</pub-id><pub-id pub-id-type="pmid">32877576</pub-id><pub-id pub-id-type="pmcid">PMC7494251</pub-id></element-citation></ref><ref id="CR55"><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kempuraj</surname><given-names>D</given-names></name><name name-style="western"><surname>Thangavel</surname><given-names>R</given-names></name><name name-style="western"><surname>Kempuraj</surname><given-names>DD</given-names></name><etal/></person-group><article-title>Neuroprotective effects of flavone luteolin in neuroinflammation and neurotrauma</article-title><source>BioFactors</source><year>2021</year><volume>47</volume><fpage>190</fpage><lpage>197</lpage><pub-id pub-id-type="doi">10.1002/biof.1687</pub-id><pub-id pub-id-type="pmid">33098588</pub-id></element-citation></ref><ref id="CR56"><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Khan</surname><given-names>S</given-names></name><name name-style="western"><surname>Siddique</surname><given-names>R</given-names></name><name name-style="western"><surname>Shereen</surname><given-names>MA</given-names></name><etal/></person-group><article-title>Emergence of a novel coronavirus, severe acute respiratory syndrome coronavirus 2: biology and therapeutic options</article-title><source>J Clin Microbiol</source><year>2020</year><volume>58</volume><issue>5</issue><fpage>e00187</fpage><lpage>20</lpage><pub-id pub-id-type="doi">10.1128/JCM.00187-20</pub-id><pub-id pub-id-type="pmid">32161092</pub-id><pub-id pub-id-type="pmcid">PMC7180238</pub-id></element-citation></ref><ref id="CR57"><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Khanal</surname><given-names>P</given-names></name><name name-style="western"><surname>Duyu</surname><given-names>T</given-names></name><name name-style="western"><surname>Patil</surname><given-names>B</given-names></name><etal/></person-group><article-title>In silico screening of JAK-STAT modulators from the antiviral plants of Indian traditional system of medicine with the potential to inhibit 2019 novel coronavirus</article-title><source>3 Biotech</source><year>2021</year><volume>11</volume><issue>3</issue><fpage>1</fpage><lpage>18</lpage><pub-id pub-id-type="doi">10.1007/s13205-021-02664-4</pub-id><pub-id pub-id-type="pmcid">PMC7869079</pub-id><pub-id pub-id-type="pmid">33585152</pub-id></element-citation></ref><ref id="CR59"><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kishore</surname><given-names>V</given-names></name><name name-style="western"><surname>Sastry Yarla</surname><given-names>N</given-names></name><name name-style="western"><surname>Bishayee</surname><given-names>A</given-names></name><etal/></person-group><article-title>Multi-targeting andrographolide and its natural analogs as potential therapeutic agents</article-title><source>Curr Top Med Chem</source><year>2017</year><volume>17</volume><fpage>845</fpage><lpage>857</lpage><pub-id pub-id-type="doi">10.2174/1568026616666160927150452</pub-id><pub-id pub-id-type="pmid">27697058</pub-id></element-citation></ref><ref id="CR200"><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kounis</surname><given-names>Ng</given-names></name><name name-style="western"><surname>Koniari</surname><given-names>I</given-names></name><name name-style="western"><surname>De Gregorio</surname><given-names>C</given-names></name><etal/></person-group><article-title>Allergic reactions to current available COVID-19 vaccinations: pathophysiology, causality, and therapeutic considerations</article-title><source>Vaccines</source><year>2021</year><volume>9</volume><fpage>221</fpage><lpage>239</lpage><pub-id pub-id-type="doi">10.3390/vaccines9030221</pub-id><pub-id pub-id-type="pmid">33807579</pub-id><pub-id pub-id-type="pmcid">PMC7999280</pub-id></element-citation></ref><ref id="CR60"><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kumar</surname><given-names>S</given-names></name><name name-style="western"><surname>Yadav</surname><given-names>M</given-names></name><name name-style="western"><surname>Yadav</surname><given-names>A</given-names></name><etal/></person-group><article-title>Antiplasmodial potential and quantification of aloin and aloe-emodin in <italic toggle="yes">Aloe vera</italic> collected from different climatic regions of India</article-title><source>BMC Complement Altern Med</source><year>2017</year><volume>17</volume><fpage>1</fpage><lpage>10</lpage><pub-id pub-id-type="doi">10.1186/s12906-017-1883-0</pub-id><pub-id pub-id-type="pmid">28716028</pub-id><pub-id pub-id-type="pmcid">PMC5514507</pub-id></element-citation></ref><ref id="CR61"><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lai</surname><given-names>C-C</given-names></name><name name-style="western"><surname>Shih</surname><given-names>T-P</given-names></name><name name-style="western"><surname>Ko</surname><given-names>W-C</given-names></name><etal/></person-group><article-title>Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and coronavirus disease-2019 (COVID-19): the epidemic and the challenges</article-title><source>Int J Antimicrob Agents</source><year>2020</year><volume>55</volume><fpage>105924</fpage><pub-id pub-id-type="doi">10.1016/j.ijantimicag.2020.105924</pub-id><pub-id pub-id-type="pmid">32081636</pub-id><pub-id pub-id-type="pmcid">PMC7127800</pub-id></element-citation></ref><ref id="CR62"><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lammers</surname><given-names>T</given-names></name><name name-style="western"><surname>Sofias</surname><given-names>AM</given-names></name><name name-style="western"><surname>van der Meel</surname><given-names>R</given-names></name><etal/></person-group><article-title>Dexamethasone nanomedicines for COVID-19</article-title><source>Nat Nanotechnol</source><year>2020</year><volume>15</volume><fpage>622</fpage><lpage>624</lpage><pub-id pub-id-type="doi">10.1038/s41565-020-0752-z</pub-id><pub-id pub-id-type="pmid">32747742</pub-id><pub-id pub-id-type="pmcid">PMC7116110</pub-id></element-citation></ref><ref id="CR63"><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ledford</surname><given-names>H</given-names></name></person-group><article-title>COVID vaccines and blood clots: five key questions</article-title><source>Nature</source><year>2021</year><volume>592</volume><fpage>495</fpage><lpage>496</lpage><pub-id pub-id-type="doi">10.1038/d41586-021-00998-w</pub-id><pub-id pub-id-type="pmid">33864049</pub-id></element-citation></ref><ref id="CR64"><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lee</surname><given-names>HJ</given-names></name><name name-style="western"><surname>Lee</surname><given-names>HK</given-names></name><name name-style="western"><surname>Lim</surname><given-names>E</given-names></name><etal/></person-group><article-title>Synergistic effect of lignin/polypropylene as a compatibilizer in multiphase eco-composites</article-title><source>Compos Sci Technol</source><year>2015</year><volume>118</volume><fpage>193</fpage><lpage>197</lpage><pub-id pub-id-type="doi">10.1016/j.compscitech.2015.08.018</pub-id></element-citation></ref><ref id="CR65"><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Li</surname><given-names>W</given-names></name><name name-style="western"><surname>Hulswit</surname><given-names>RJ</given-names></name><name name-style="western"><surname>Kenney</surname><given-names>SP</given-names></name><etal/></person-group><article-title>Broad receptor engagement of an emerging global coronavirus may potentiate its diverse cross-species transmissibility</article-title><source>Proc Natl Acad Sci</source><year>2018</year><volume>115</volume><fpage>E5135</fpage><lpage>E5143</lpage><pub-id pub-id-type="pmid">29760102</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1073/pnas.1802879115</pub-id><pub-id pub-id-type="pmcid">PMC5984533</pub-id></element-citation></ref><ref id="CR66"><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Liang</surname><given-names>Z</given-names></name><name name-style="western"><surname>Zhu</surname><given-names>H</given-names></name><name name-style="western"><surname>Wang</surname><given-names>X</given-names></name><etal/></person-group><article-title>Adjuvants for coronavirus vaccines</article-title><source>Front Immunol</source><year>2020</year><volume>11</volume><fpage>2896</fpage><pub-id pub-id-type="doi">10.3389/fimmu.2020.589833</pub-id><pub-id pub-id-type="pmcid">PMC7677582</pub-id><pub-id pub-id-type="pmid">33240278</pub-id></element-citation></ref><ref id="CR67"><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lin</surname><given-names>S-C</given-names></name><name name-style="western"><surname>Ho</surname><given-names>C-T</given-names></name><name name-style="western"><surname>Chuo</surname><given-names>W-H</given-names></name><etal/></person-group><article-title>Effective inhibition of MERS-CoV infection by resveratrol</article-title><source>BMC Infect Dis</source><year>2017</year><volume>17</volume><fpage>1</fpage><lpage>10</lpage><pub-id pub-id-type="doi">10.1186/s12879-017-2253-8</pub-id><pub-id pub-id-type="pmid">28193191</pub-id><pub-id pub-id-type="pmcid">PMC5307780</pub-id></element-citation></ref><ref id="CR68"><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Liu</surname><given-names>F</given-names></name><name name-style="western"><surname>Li</surname><given-names>Y</given-names></name><name name-style="western"><surname>Yang</surname><given-names>Y</given-names></name><etal/></person-group><article-title>Study on mechanism of matrine in treatment of COVID-19 combined with liver injury by network pharmacology and molecular docking technology</article-title><source>Drug Delivery</source><year>2021</year><volume>28</volume><fpage>325</fpage><lpage>342</lpage><pub-id pub-id-type="doi">10.1080/10717544.2021.1879313</pub-id><pub-id pub-id-type="pmid">33517789</pub-id><pub-id pub-id-type="pmcid">PMC8735880</pub-id></element-citation></ref><ref id="CR69"><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Logunov</surname><given-names>DY</given-names></name><name name-style="western"><surname>Dolzhikova</surname><given-names>IV</given-names></name><name name-style="western"><surname>Zubkova</surname><given-names>OV</given-names></name><etal/></person-group><article-title>Safety and immunogenicity of an rAd26 and rAd5 vector-based heterologous prime-boost COVID-19 vaccine in two formulations: two open, non-randomised phase 1/2 studies from Russia</article-title><source>Lancet</source><year>2020</year><volume>396</volume><fpage>887</fpage><lpage>897</lpage><pub-id pub-id-type="doi">10.1016/S0140-6736(20)31866-3</pub-id><pub-id pub-id-type="pmid">32896291</pub-id><pub-id pub-id-type="pmcid">PMC7471804</pub-id></element-citation></ref><ref id="CR70"><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Logunov</surname><given-names>DY</given-names></name><name name-style="western"><surname>Dolzhikova</surname><given-names>IV</given-names></name><name name-style="western"><surname>Shcheblyakov</surname><given-names>DV</given-names></name><etal/></person-group><article-title>Safety and efficacy of an rAd26 and rAd5 vector-based heterologous prime-boost COVID-19 vaccine: an interim analysis of a randomised controlled phase 3 trial in Russia</article-title><source>Lancet</source><year>2021</year><volume>397</volume><fpage>671</fpage><lpage>681</lpage><pub-id pub-id-type="doi">10.1016/S0140-6736(21)00234-8</pub-id><pub-id pub-id-type="pmid">33545094</pub-id><pub-id pub-id-type="pmcid">PMC7852454</pub-id></element-citation></ref><ref id="CR71"><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lu</surname><given-names>R</given-names></name><name name-style="western"><surname>Zhao</surname><given-names>X</given-names></name><name name-style="western"><surname>Li</surname><given-names>J</given-names></name><etal/></person-group><article-title>Genomic characterisation and epidemiology of 2019 novel coronavirus: implications for virus origins and receptor binding</article-title><source>Lancet</source><year>2020</year><volume>395</volume><fpage>565</fpage><lpage>574</lpage><pub-id pub-id-type="doi">10.1016/S0140-6736(20)30251-8</pub-id><pub-id pub-id-type="pmid">32007145</pub-id><pub-id pub-id-type="pmcid">PMC7159086</pub-id></element-citation></ref><ref id="CR72"><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Luo</surname><given-names>P</given-names></name><name name-style="western"><surname>Liu</surname><given-names>D</given-names></name><name name-style="western"><surname>Li</surname><given-names>J</given-names></name></person-group><article-title>Pharmacological perspective: glycyrrhizin may be an efficacious therapeutic agent for COVID-19</article-title><source>Int J Antimicrob Agents</source><year>2020</year><volume>55</volume><fpage>105995</fpage><pub-id pub-id-type="doi">10.1016/j.ijantimicag.2020.105995</pub-id><pub-id pub-id-type="pmid">32335281</pub-id><pub-id pub-id-type="pmcid">PMC7180159</pub-id></element-citation></ref><ref id="CR73"><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Luo</surname><given-names>P</given-names></name><name name-style="western"><surname>Liu</surname><given-names>Y</given-names></name><name name-style="western"><surname>Qiu</surname><given-names>L</given-names></name><etal/></person-group><article-title>Tocilizumab treatment in COVID-19: a single center experience</article-title><source>J Med Virol</source><year>2020</year><volume>92</volume><fpage>814</fpage><lpage>818</lpage><pub-id pub-id-type="doi">10.1002/jmv.25801</pub-id><pub-id pub-id-type="pmid">32253759</pub-id><pub-id pub-id-type="pmcid">PMC7262125</pub-id></element-citation></ref><ref id="CR74"><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lurie</surname><given-names>N</given-names></name><name name-style="western"><surname>Saville</surname><given-names>M</given-names></name><name name-style="western"><surname>Hatchett</surname><given-names>R</given-names></name><etal/></person-group><article-title>Developing Covid-19 vaccines at pandemic speed</article-title><source>N Engl J Med</source><year>2020</year><volume>382</volume><fpage>1969</fpage><lpage>1973</lpage><pub-id pub-id-type="doi">10.1056/NEJMp2005630</pub-id><pub-id pub-id-type="pmid">32227757</pub-id></element-citation></ref><ref id="CR75"><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Majumder</surname><given-names>J</given-names></name><name name-style="western"><surname>Minko</surname><given-names>T</given-names></name></person-group><article-title>Recent developments on therapeutic and diagnostic approaches for COVID-19</article-title><source>AAPS J</source><year>2021</year><volume>23</volume><fpage>1</fpage><lpage>22</lpage><pub-id pub-id-type="doi">10.1208/s12248-020-00532-2</pub-id><pub-id pub-id-type="pmcid">PMC7784226</pub-id><pub-id pub-id-type="pmid">33400058</pub-id></element-citation></ref><ref id="CR76"><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Malik</surname><given-names>Z</given-names></name><name name-style="western"><surname>Parveen</surname><given-names>R</given-names></name><name name-style="western"><surname>Parveen</surname><given-names>B</given-names></name><etal/></person-group><article-title>Anticancer potential of andrographolide from Andrographis paniculata (Burm. F.) Nees and its mechanisms of action</article-title><source>J Ethnopharmacol</source><year>2021</year><volume>272</volume><fpage>113936</fpage><pub-id pub-id-type="doi">10.1016/j.jep.2021.113936</pub-id><pub-id pub-id-type="pmid">33610710</pub-id></element-citation></ref><ref id="CR77"><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Mason</surname><given-names>RJ</given-names></name></person-group><article-title>Pathogenesis of COVID-19 from a cell biology perspective</article-title><source>Eur Respir Soc</source><year>2020</year><volume>55</volume><fpage>2000607</fpage><pub-id pub-id-type="doi">10.1183/13993003.00607-2020</pub-id><pub-id pub-id-type="pmcid">PMC7144260</pub-id><pub-id pub-id-type="pmid">32269085</pub-id></element-citation></ref><ref id="CR78"><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Mollaei</surname><given-names>S</given-names></name><name name-style="western"><surname>Khanehbarndaz</surname><given-names>O</given-names></name><name name-style="western"><surname>Gerami-Khashal</surname><given-names>Z</given-names></name><etal/></person-group><article-title>Molecular identification and phytochemical screening of endophytic fungi isolated from Lithospermum officinale L. roots: a new source of shikonin</article-title><source>Phytochemistry</source><year>2019</year><volume>168</volume><fpage>112116</fpage><pub-id pub-id-type="doi">10.1016/j.phytochem.2019.112116</pub-id><pub-id pub-id-type="pmid">31513947</pub-id></element-citation></ref><ref id="CR79"><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Nazari</surname><given-names>S</given-names></name><name name-style="western"><surname>Rameshrad</surname><given-names>M</given-names></name><name name-style="western"><surname>Hosseinzadeh</surname><given-names>H</given-names></name></person-group><article-title>Toxicological effects of Glycyrrhiza glabra (licorice): a review</article-title><source>Phytother Res</source><year>2017</year><volume>31</volume><fpage>1635</fpage><lpage>1650</lpage><pub-id pub-id-type="doi">10.1002/ptr.5893</pub-id><pub-id pub-id-type="pmid">28833680</pub-id></element-citation></ref><ref id="CR80"><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Nguyen</surname><given-names>TTH</given-names></name><name name-style="western"><surname>Woo</surname><given-names>H-J</given-names></name><name name-style="western"><surname>Kang</surname><given-names>H-K</given-names></name><etal/></person-group><article-title>Flavonoid-mediated inhibition of SARS coronavirus 3C-like protease expressed in Pichia pastoris</article-title><source>Biotech Lett</source><year>2012</year><volume>34</volume><fpage>831</fpage><lpage>838</lpage><pub-id pub-id-type="doi">10.1007/s10529-011-0845-8</pub-id><pub-id pub-id-type="pmcid">PMC7087583</pub-id><pub-id pub-id-type="pmid">22350287</pub-id></element-citation></ref><ref id="CR81"><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Okoshi</surname><given-names>K</given-names></name><name name-style="western"><surname>Uekusa</surname><given-names>Y</given-names></name><name name-style="western"><surname>Narukawa</surname><given-names>Y</given-names></name><etal/></person-group><article-title>Solubility enhancement of berberine&#8211;baicalin complex by the constituents of Gardenia Fruit</article-title><source>J Nat Med</source><year>2021</year><volume>75</volume><fpage>76</fpage><lpage>83</lpage><pub-id pub-id-type="doi">10.1007/s11418-020-01446-1</pub-id><pub-id pub-id-type="pmid">32857337</pub-id><pub-id pub-id-type="pmcid">PMC8933372</pub-id></element-citation></ref><ref id="CR83"><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Palasca</surname><given-names>O</given-names></name><name name-style="western"><surname>Santos</surname><given-names>A</given-names></name><name name-style="western"><surname>Stolte</surname><given-names>C</given-names></name><etal/></person-group><article-title>TISSUES 2.0: an integrative web resource on mammalian tissue expression</article-title><source>Database</source><year>2018</year><volume>2018</volume><fpage>1</fpage><lpage>12</lpage><pub-id pub-id-type="doi">10.1093/database/bay003</pub-id><pub-id pub-id-type="pmcid">PMC5808782</pub-id><pub-id pub-id-type="pmid">29617745</pub-id></element-citation></ref><ref id="CR84"><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Petramfar</surname><given-names>P</given-names></name><name name-style="western"><surname>Hajari</surname><given-names>F</given-names></name><name name-style="western"><surname>Yousefi</surname><given-names>G</given-names></name><etal/></person-group><article-title>Efficacy of oral administration of licorice as an adjunct therapy on improving the symptoms of patients with Parkinson&#8217;s disease, a randomized double blinded clinical trial</article-title><source>J Ethnopharmacol</source><year>2020</year><volume>247</volume><fpage>112226</fpage><pub-id pub-id-type="doi">10.1016/j.jep.2019.112226</pub-id><pub-id pub-id-type="pmid">31574343</pub-id></element-citation></ref><ref id="CR85"><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Pitocco</surname><given-names>D</given-names></name><name name-style="western"><surname>Tartaglione</surname><given-names>L</given-names></name><name name-style="western"><surname>Viti</surname><given-names>L</given-names></name><etal/></person-group><article-title>SARS-CoV-2 and DPP4 inhibition: is it time to pray for Janus Bifrons?</article-title><source>Diabetes Res Clin Pract</source><year>2020</year><volume>163</volume><fpage>108162</fpage><pub-id pub-id-type="doi">10.1016/j.diabres.2020.108162</pub-id><pub-id pub-id-type="pmid">32335097</pub-id><pub-id pub-id-type="pmcid">PMC7179491</pub-id></element-citation></ref><ref id="CR86"><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Polack</surname><given-names>FP</given-names></name><name name-style="western"><surname>Thomas</surname><given-names>SJ</given-names></name><name name-style="western"><surname>Kitchin</surname><given-names>N</given-names></name><etal/></person-group><article-title>Safety and efficacy of the BNT162b2 mRNA Covid-19 vaccine</article-title><source>N Engl J Med</source><year>2020</year><volume>383</volume><fpage>2603</fpage><lpage>2615</lpage><pub-id pub-id-type="doi">10.1056/NEJMoa2034577</pub-id><pub-id pub-id-type="pmid">33301246</pub-id><pub-id pub-id-type="pmcid">PMC7745181</pub-id></element-citation></ref><ref id="CR87"><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Quer</surname><given-names>G</given-names></name><name name-style="western"><surname>Radin</surname><given-names>JM</given-names></name><name name-style="western"><surname>Gadaleta</surname><given-names>M</given-names></name><etal/></person-group><article-title>Wearable sensor data and self-reported symptoms for COVID-19 detection</article-title><source>Nat Med</source><year>2021</year><volume>27</volume><fpage>73</fpage><lpage>77</lpage><pub-id pub-id-type="doi">10.1038/s41591-020-1123-x</pub-id><pub-id pub-id-type="pmid">33122860</pub-id></element-citation></ref><ref id="CR88"><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Rao</surname><given-names>YK</given-names></name><name name-style="western"><surname>Vimalamma</surname><given-names>G</given-names></name><name name-style="western"><surname>Rao</surname><given-names>CV</given-names></name><etal/></person-group><article-title>Flavonoids and andrographolides from Andrographis paniculata</article-title><source>Phytochemistry</source><year>2004</year><volume>65</volume><fpage>2317</fpage><lpage>2321</lpage><pub-id pub-id-type="doi">10.1016/j.phytochem.2004.05.008</pub-id><pub-id pub-id-type="pmid">15381002</pub-id></element-citation></ref><ref id="CR89"><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ray</surname><given-names>S</given-names></name><name name-style="western"><surname>Maunsell</surname><given-names>JH</given-names></name></person-group><article-title>Different origins of gamma rhythm and high-gamma activity in macaque visual cortex</article-title><source>PLoS Biol</source><year>2011</year><volume>9</volume><fpage>e1000610</fpage><pub-id pub-id-type="doi">10.1371/journal.pbio.1000610</pub-id><pub-id pub-id-type="pmid">21532743</pub-id><pub-id pub-id-type="pmcid">PMC3075230</pub-id></element-citation></ref><ref id="CR90"><mixed-citation publication-type="other">Reche A, Kolse R, Gupta S et al (2020) Therapeutic options for COVID&#8211;19: Pandemic&#8211;a review. Int J Res Pharmaceut Sci 11(Special Issue 1). 10.26452/ijrps.v11iSPL1.2802</mixed-citation></ref><ref id="CR91"><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Russell</surname><given-names>CD</given-names></name><name name-style="western"><surname>Millar</surname><given-names>JE</given-names></name><name name-style="western"><surname>Baillie</surname><given-names>JK</given-names></name></person-group><article-title>Clinical evidence does not support corticosteroid treatment for 2019-nCoV lung injury</article-title><source>Lancet</source><year>2020</year><volume>395</volume><fpage>473</fpage><lpage>475</lpage><pub-id pub-id-type="doi">10.1016/S0140-6736(20)30317-2</pub-id><pub-id pub-id-type="pmid">32043983</pub-id><pub-id pub-id-type="pmcid">PMC7134694</pub-id></element-citation></ref><ref id="CR92"><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ryu</surname><given-names>YB</given-names></name><name name-style="western"><surname>Jeong</surname><given-names>HJ</given-names></name><name name-style="western"><surname>Kim</surname><given-names>JH</given-names></name><etal/></person-group><article-title>Biflavonoids from Torreya nucifera displaying SARS-CoV 3CLpro inhibition</article-title><source>Bioorg Med Chem</source><year>2010</year><volume>18</volume><fpage>7940</fpage><lpage>7947</lpage><pub-id pub-id-type="doi">10.1016/j.bmc.2010.09.035</pub-id><pub-id pub-id-type="pmid">20934345</pub-id><pub-id pub-id-type="pmcid">PMC7126309</pub-id></element-citation></ref><ref id="CR93"><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Sadoff</surname><given-names>J</given-names></name><name name-style="western"><surname>Gray</surname><given-names>G</given-names></name><name name-style="western"><surname>Vandebosch</surname><given-names>A</given-names></name><etal/></person-group><article-title>Safety and efficacy of single-dose Ad26. COV2. S vaccine against Covid-19</article-title><source>New Engl J Med</source><year>2021</year><volume>384</volume><issue>23</issue><fpage>2187</fpage><lpage>2201</lpage><pub-id pub-id-type="doi">10.1056/NEJMoa2101544</pub-id><pub-id pub-id-type="pmid">33882225</pub-id><pub-id pub-id-type="pmcid">PMC8220996</pub-id></element-citation></ref><ref id="CR94"><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>SchultzN</surname><given-names>H</given-names></name><name name-style="western"><surname>S&#248;rvollI</surname><given-names>H</given-names></name><name name-style="western"><surname>Michelsen</surname><given-names>AE</given-names></name><etal/></person-group><article-title>Thrombosis and thrombocytopenia after ChAdOx1 nCoV-19 vaccination</article-title><source>New Engl J Med</source><year>2010</year><volume>384</volume><issue>22</issue><fpage>2124</fpage><lpage>2130</lpage><pub-id pub-id-type="doi">10.1056/NEJMoa2104882</pub-id><pub-id pub-id-type="pmcid">PMC8112568</pub-id><pub-id pub-id-type="pmid">33835768</pub-id></element-citation></ref><ref id="CR95"><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Schwarz</surname><given-names>S</given-names></name><name name-style="western"><surname>Wang</surname><given-names>K</given-names></name><name name-style="western"><surname>Yu</surname><given-names>W</given-names></name><etal/></person-group><article-title>Emodin inhibits current through SARS-associated coronavirus 3a protein</article-title><source>Antiviral Res</source><year>2011</year><volume>90</volume><fpage>64</fpage><lpage>69</lpage><pub-id pub-id-type="doi">10.1016/j.antiviral.2011.02.008</pub-id><pub-id pub-id-type="pmid">21356245</pub-id><pub-id pub-id-type="pmcid">PMC7114100</pub-id></element-citation></ref><ref id="CR96"><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Scully</surname><given-names>M</given-names></name><name name-style="western"><surname>Singh</surname><given-names>D</given-names></name><name name-style="western"><surname>Lown</surname><given-names>R</given-names></name><etal/></person-group><article-title>Pathologic antibodies to platelet factor 4 after ChAdOx1 nCoV-19 vaccination</article-title><source>New Engl J Med</source><year>2021</year><volume>23</volume><fpage>2202</fpage><lpage>2211</lpage><pub-id pub-id-type="doi">10.1056/NEJMoa2105385</pub-id><pub-id pub-id-type="pmcid">PMC8112532</pub-id><pub-id pub-id-type="pmid">33861525</pub-id></element-citation></ref><ref id="CR97"><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Selmi</surname><given-names>S</given-names></name><name name-style="western"><surname>Rtibi</surname><given-names>K</given-names></name><name name-style="western"><surname>Grami</surname><given-names>D</given-names></name><etal/></person-group><article-title>Protective effects of orange (<italic toggle="yes">Citrus sinensis</italic> L.) peel aqueous extract and hesperidin on oxidative stress and peptic ulcer induced by alcohol in rat</article-title><source>Lipids Health Dis</source><year>2017</year><volume>16</volume><fpage>1</fpage><lpage>12</lpage><pub-id pub-id-type="doi">10.1186/s12944-017-0546-y</pub-id><pub-id pub-id-type="pmid">28806973</pub-id><pub-id pub-id-type="pmcid">PMC5556677</pub-id></element-citation></ref><ref id="CR98"><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Sharma</surname><given-names>O</given-names></name><name name-style="western"><surname>Sultan</surname><given-names>AA</given-names></name><name name-style="western"><surname>Ding</surname><given-names>H</given-names></name><name name-style="western"><surname>Triggle</surname><given-names>CR</given-names></name></person-group><article-title>A review of the progress and challenges of developing a vaccine for COVID-19</article-title><source>Front Immunol</source><year>2020</year><volume>11</volume><fpage>2413</fpage><pub-id pub-id-type="doi">10.3389/fimmu.2020.585354</pub-id><pub-id pub-id-type="pmcid">PMC7591699</pub-id><pub-id pub-id-type="pmid">33163000</pub-id></element-citation></ref><ref id="CR99"><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Shaw</surname><given-names>CA</given-names></name><name name-style="western"><surname>Li</surname><given-names>D</given-names></name><name name-style="western"><surname>Tomljenovic</surname><given-names>L</given-names></name></person-group><article-title>Are there negative CNS impacts of aluminum adjuvants used in vaccines and immunotherapy?</article-title><source>Immunotherapy</source><year>2014</year><volume>6</volume><issue>10</issue><fpage>1055</fpage><lpage>1071</lpage><pub-id pub-id-type="doi">10.2217/imt.14.81</pub-id><pub-id pub-id-type="pmid">25428645</pub-id></element-citation></ref><ref id="CR100"><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Shereen</surname><given-names>MA</given-names></name><name name-style="western"><surname>Khan</surname><given-names>S</given-names></name><name name-style="western"><surname>Kazmi</surname><given-names>A</given-names></name><etal/></person-group><article-title>COVID-19 infection: origin, transmission, and characteristics of human coronaviruses</article-title><source>J Adv Res</source><year>2020</year><volume>24</volume><fpage>91</fpage><lpage>98</lpage><pub-id pub-id-type="doi">10.1016/j.jare.2020.03.005</pub-id><pub-id pub-id-type="pmid">32257431</pub-id><pub-id pub-id-type="pmcid">PMC7113610</pub-id></element-citation></ref><ref id="CR101"><mixed-citation publication-type="other">Shinde V, Bhikha S, Hoosain Z et al (2021) Efficacy of NVX-CoV2373 covid-19 vaccine against the b. 1.351 variant. New Engl J Med<pub-id pub-id-type="doi" assigning-authority="pmc">10.1056/NEJMoa2103055</pub-id><pub-id pub-id-type="pmcid">PMC8091623</pub-id><pub-id pub-id-type="pmid">33951374</pub-id></mixed-citation></ref><ref id="CR102"><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Shoenfeld</surname><given-names>Y</given-names></name><name name-style="western"><surname>Agmon-Levin</surname><given-names>N</given-names></name></person-group><article-title>&#8216;ASIA&#8217;&#8211;autoimmune/inflammatory syndrome induced by adjuvants</article-title><source>J Autoimmun</source><year>2011</year><volume>36</volume><issue>1</issue><fpage>4</fpage><lpage>8</lpage><pub-id pub-id-type="doi">10.1016/j.jaut.2010.07.003</pub-id><pub-id pub-id-type="pmid">20708902</pub-id></element-citation></ref><ref id="CR103"><mixed-citation publication-type="other">Sim SK (2019) 4 Flavonoid glycosides, Medicinal plant glycosides<italic toggle="yes">.</italic> University of Toronto Press, p 55&#8211;62</mixed-citation></ref><ref id="CR104"><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Soiza</surname><given-names>RL</given-names></name><name name-style="western"><surname>SciclunaC</surname><given-names>TEC</given-names></name></person-group><article-title>Efficacy and safety of COVID-19 vaccines in older people</article-title><source>Age Ageing</source><year>2021</year><volume>50</volume><issue>2</issue><fpage>279</fpage><lpage>283</lpage><pub-id pub-id-type="doi">10.1093/ageing/afaa274</pub-id><pub-id pub-id-type="pmid">33320183</pub-id><pub-id pub-id-type="pmcid">PMC7799251</pub-id></element-citation></ref><ref id="CR105"><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Stebbing</surname><given-names>J</given-names></name><name name-style="western"><surname>Phelan</surname><given-names>A</given-names></name><name name-style="western"><surname>Griffin</surname><given-names>I</given-names></name><etal/></person-group><article-title>COVID-19: combining antiviral and anti-inflammatory treatments</article-title><source>Lancet Infect Dis</source><year>2020</year><volume>20</volume><fpage>400</fpage><lpage>402</lpage><pub-id pub-id-type="doi">10.1016/S1473-3099(20)30132-8</pub-id><pub-id pub-id-type="pmid">32113509</pub-id><pub-id pub-id-type="pmcid">PMC7158903</pub-id></element-citation></ref><ref id="CR106"><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Su</surname><given-names>H</given-names></name><name name-style="western"><surname>Yao</surname><given-names>S</given-names></name><name name-style="western"><surname>Zhao</surname><given-names>W</given-names></name><etal/></person-group><article-title>Discovery of baicalin and baicalein as novel, natural product inhibitors of SARS-CoV-2 3CL protease in vitro</article-title><source>BioRxiv</source><year>2020</year><volume>209</volume><fpage>236</fpage></element-citation></ref><ref id="CR107"><mixed-citation publication-type="other">Szopa A, Kokotkiewicz A, Klimek-Szczykutowicz M et al (2021) Different types of in vitro cultures of Schisandra chinensis and its cultivar (S. chinensis cv. Sadova): a rich potential source of specific lignans and phenolic compounds. Plant Cell and Tissue Differentiation and Secondary Metabolites: fundamentals and Applications: 309&#8211;336.</mixed-citation></ref><ref id="CR108"><mixed-citation publication-type="other">Tallei TE, Tumilaar SG, Niode NJ et al (2020) Potential of plant bioactive compounds as SARS-CoV-2 main protease (Mpro) and spike (S) glycoprotein inhibitors: a molecular docking study. Scientifica 2020<pub-id pub-id-type="doi" assigning-authority="pmc">10.1155/2020/6307457</pub-id><pub-id pub-id-type="pmcid">PMC7773461</pub-id><pub-id pub-id-type="pmid">33425427</pub-id></mixed-citation></ref><ref id="CR109"><mixed-citation publication-type="other">Tan B K, Mainbourg S, Friggeri A et al (2021) Arterial and venous thromboembolism in COVID-19: a study-level meta-analysis. Thorax.<pub-id pub-id-type="doi" assigning-authority="pmc">10.1136/thoraxjnl-2020-215383</pub-id><pub-id pub-id-type="pmid">33622981</pub-id></mixed-citation></ref><ref id="CR110"><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Tseng</surname><given-names>CT</given-names></name><name name-style="western"><surname>Sbrana</surname><given-names>E</given-names></name><name name-style="western"><surname>Iwata-Yoshikawa, </surname></name><etal/></person-group><article-title>Immunization with SARS coronavirus vaccines leads to pulmonary immunopathology on challenge with the SARS virus</article-title><source>PLoS One</source><year>2012</year><volume>7</volume><fpage>e35421</fpage><pub-id pub-id-type="doi">10.1371/journal.pone.0035421</pub-id><pub-id pub-id-type="pmid">22536382</pub-id><pub-id pub-id-type="pmcid">PMC3335060</pub-id></element-citation></ref><ref id="CR111"><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Udwadia</surname><given-names>ZF</given-names></name><name name-style="western"><surname>Singh</surname><given-names>P</given-names></name><name name-style="western"><surname>Barkate</surname><given-names>H</given-names></name><etal/></person-group><article-title>Efficacy and safety of favipiravir, an oral RNA-dependent RNA polymerase inhibitor, in mild-to-moderate COVID-19: a randomized, comparative, open-label, multicenter, phase 3 clinical trial</article-title><source>Int J Infect Dis</source><year>2021</year><volume>103</volume><fpage>62</fpage><lpage>71</lpage><pub-id pub-id-type="doi">10.1016/j.ijid.2020.11.142</pub-id><pub-id pub-id-type="pmid">33212256</pub-id><pub-id pub-id-type="pmcid">PMC7668212</pub-id></element-citation></ref><ref id="CR112"><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Vickers</surname><given-names>ER</given-names></name><name name-style="western"><surname>Mcclure</surname><given-names>DL</given-names></name><name name-style="western"><surname>Naleway</surname><given-names>AL</given-names></name><etal/></person-group><article-title>Risk of venous thromboembolism following influenza vaccination in adults aged 50 years and older in the Vaccine Safety Datalink</article-title><source>Vaccine</source><year>2017</year><volume>35</volume><fpage>5872</fpage><lpage>5877</lpage><pub-id pub-id-type="doi">10.1016/j.vaccine.2017.08.086</pub-id><pub-id pub-id-type="pmid">28888342</pub-id><pub-id pub-id-type="pmcid">PMC6508529</pub-id></element-citation></ref><ref id="CR113"><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Vijayvargiya</surname><given-names>P</given-names></name><name name-style="western"><surname>Garrigos</surname><given-names>ZE</given-names></name><name name-style="western"><surname>Almeida</surname><given-names>NEC</given-names></name><etal/></person-group><article-title>Treatment considerations for COVID-19: a critical review of the evidence (or lack thereof)</article-title><source>Mayo Clin Proc</source><year>2020</year><volume>95</volume><issue>7</issue><fpage>1454</fpage><lpage>1466</lpage><pub-id pub-id-type="doi">10.1016/j.mayocp.2020.04.027</pub-id><pub-id pub-id-type="pmid">32561148</pub-id><pub-id pub-id-type="pmcid">PMC7190528</pub-id></element-citation></ref><ref id="CR114"><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Voysey</surname><given-names>M</given-names></name><name name-style="western"><surname>Clemens</surname><given-names>SAC</given-names></name><name name-style="western"><surname>Madhi</surname><given-names>SA</given-names></name><etal/></person-group><article-title>Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK</article-title><source>Lancet</source><year>2021</year><volume>397</volume><fpage>99</fpage><lpage>111</lpage><pub-id pub-id-type="doi">10.1016/S0140-6736(20)32661-1</pub-id><pub-id pub-id-type="pmid">33306989</pub-id><pub-id pub-id-type="pmcid">PMC7723445</pub-id></element-citation></ref><ref id="CR115"><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Walls</surname><given-names>AC</given-names></name><name name-style="western"><surname>Park</surname><given-names>Y-J</given-names></name><name name-style="western"><surname>Tortorici</surname><given-names>MA</given-names></name><etal/></person-group><article-title>Structure, function, and antigenicity of the SARS-CoV-2 spike glycoprotein</article-title><source>Cell</source><year>2020</year><volume>181</volume><fpage>281</fpage><lpage>292 e286</lpage><pub-id pub-id-type="doi">10.1016/j.cell.2020.02.058</pub-id><pub-id pub-id-type="pmid">32155444</pub-id><pub-id pub-id-type="pmcid">PMC7102599</pub-id></element-citation></ref><ref id="CR116"><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wang</surname><given-names>Q</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>Y</given-names></name><name name-style="western"><surname>Wu</surname><given-names>L</given-names></name><etal/></person-group><article-title>Structural and functional basis of SARS-CoV-2 entry by using human ACE2</article-title><source>Cell</source><year>2020</year><volume>181</volume><fpage>894</fpage><lpage>904 e899</lpage><pub-id pub-id-type="doi">10.1016/j.cell.2020.03.045</pub-id><pub-id pub-id-type="pmid">32275855</pub-id><pub-id pub-id-type="pmcid">PMC7144619</pub-id></element-citation></ref><ref id="CR117"><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wang</surname><given-names>C</given-names></name><name name-style="western"><surname>Li</surname><given-names>W</given-names></name><name name-style="western"><surname>Drabek</surname><given-names>D</given-names></name><etal/></person-group><article-title>A human monoclonal antibody blocking SARS-CoV-2 infection</article-title><source>Nat Commun</source><year>2020</year><volume>11</volume><fpage>1</fpage><lpage>6</lpage><pub-id pub-id-type="pmid">32366817</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41467-020-16256-y</pub-id><pub-id pub-id-type="pmcid">PMC7198537</pub-id></element-citation></ref><ref id="CR118"><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wang</surname><given-names>F</given-names></name><name name-style="western"><surname>Kream</surname><given-names>RM</given-names></name><name name-style="western"><surname>Stefano</surname><given-names>GB</given-names></name></person-group><article-title>An evidence based perspective on mRNA-SARS-CoV-2 vaccine development</article-title><source>Med Sci Monitor</source><year>2020</year><volume>26</volume><fpage>e924700</fpage><lpage>924701</lpage><pub-id pub-id-type="doi" assigning-authority="pmc">10.12659/MSM.924700</pub-id><pub-id pub-id-type="pmcid">PMC7218962</pub-id><pub-id pub-id-type="pmid">32366816</pub-id></element-citation></ref><ref id="CR119"><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wen</surname><given-names>C-C</given-names></name><name name-style="western"><surname>Kuo</surname><given-names>Y-H</given-names></name><name name-style="western"><surname>Jan</surname><given-names>J-T</given-names></name><etal/></person-group><article-title>Specific plant terpenoids and lignoids possess potent antiviral activities against severe acute respiratory syndrome coronavirus</article-title><source>J Med Chem</source><year>2007</year><volume>50</volume><fpage>4087</fpage><lpage>4095</lpage><pub-id pub-id-type="doi">10.1021/jm070295s</pub-id><pub-id pub-id-type="pmid">17663539</pub-id></element-citation></ref><ref id="CR121"><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wong</surname><given-names>AH</given-names></name><name name-style="western"><surname>Tomlinson</surname><given-names>AC</given-names></name><name name-style="western"><surname>Zhou</surname><given-names>D</given-names></name><etal/></person-group><article-title>Receptor-binding loops in alphacoronavirus adaptation and evolution</article-title><source>Nat Commun</source><year>2017</year><volume>8</volume><fpage>1</fpage><lpage>10</lpage><pub-id pub-id-type="doi">10.1038/s41467-017-01706-x</pub-id><pub-id pub-id-type="pmid">29170370</pub-id><pub-id pub-id-type="pmcid">PMC5701055</pub-id></element-citation></ref><ref id="CR122"><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wu</surname><given-names>J</given-names></name><name name-style="western"><surname>Shen</surname><given-names>J</given-names></name><name name-style="western"><surname>Han</surname><given-names>Y</given-names></name><etal/></person-group><article-title>Upregulated IL-6 indicates a Poor COVID-19 prognosis: a call for tocilizumab and convalescent plasma treatment</article-title><source>Front Immunol</source><year>2021</year><volume>12</volume><fpage>455</fpage><pub-id pub-id-type="doi" assigning-authority="pmc">10.3389/fimmu.2021.598799</pub-id><pub-id pub-id-type="pmcid">PMC7969719</pub-id><pub-id pub-id-type="pmid">33746945</pub-id></element-citation></ref><ref id="CR123"><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Xia</surname><given-names>S</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>Y</given-names></name><name name-style="western"><surname>Wang</surname><given-names>Y</given-names></name><etal/></person-group><article-title>Safety and immunogenicity of an inactivated SARS-CoV-2 vaccine, BBIBP-CorV: a randomised, double-blind, placebo-controlled, phase 1/2 trial</article-title><source>Lancet Infect Dis</source><year>2021</year><volume>21</volume><fpage>39</fpage><lpage>51</lpage><pub-id pub-id-type="doi">10.1016/S1473-3099(20)30831-8</pub-id><pub-id pub-id-type="pmid">33069281</pub-id><pub-id pub-id-type="pmcid">PMC7561304</pub-id></element-citation></ref><ref id="CR124"><mixed-citation publication-type="other">Xu Y, Lian D, Chen Y et al (2017) In vitro and in vivo antibacterial activities of patchouli alcohol, a naturally occurring tricyclic sesquiterpene, against Helicobacter pylori infection. Antimicrob Agents Chemotherap 61.<pub-id pub-id-type="doi" assigning-authority="pmc">10.1128/AAC.00122-17</pub-id><pub-id pub-id-type="pmcid">PMC5444145</pub-id><pub-id pub-id-type="pmid">28320722</pub-id></mixed-citation></ref><ref id="CR125"><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Yan</surname><given-names>H</given-names></name><name name-style="western"><surname>Ma</surname><given-names>L</given-names></name><name name-style="western"><surname>Wang</surname><given-names>H</given-names></name><etal/></person-group><article-title>Luteolin decreases the yield of influenza A virus in vitro by interfering with the coat protein I complex expression</article-title><source>J Nat Med</source><year>2019</year><volume>73</volume><fpage>487</fpage><lpage>496</lpage><pub-id pub-id-type="doi">10.1007/s11418-019-01287-7</pub-id><pub-id pub-id-type="pmid">30758716</pub-id></element-citation></ref><ref id="CR127"><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Yu</surname><given-names>Y</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>Y</given-names></name><name name-style="western"><surname>Wang</surname><given-names>S</given-names></name><etal/></person-group><article-title>Inhibition effects of patchouli alcohol against influenza a virus through targeting cellular PI3K/Akt and ERK/MAPK signaling pathways</article-title><source>Virol J</source><year>2019</year><volume>16</volume><fpage>1</fpage><lpage>16</lpage><pub-id pub-id-type="doi">10.1186/s12985-019-1266-x</pub-id><pub-id pub-id-type="pmid">31870450</pub-id><pub-id pub-id-type="pmcid">PMC6929483</pub-id></element-citation></ref><ref id="CR128"><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Yuan</surname><given-names>M</given-names></name><name name-style="western"><surname>Wu</surname><given-names>NC</given-names></name><name name-style="western"><surname>Zhu</surname><given-names>X</given-names></name><etal/></person-group><article-title>A highly conserved cryptic epitope in the receptor binding domains of SARS-CoV-2 and SARS-CoV</article-title><source>Science</source><year>2020</year><volume>368</volume><fpage>630</fpage><lpage>633</lpage><pub-id pub-id-type="doi">10.1126/science.abb7269</pub-id><pub-id pub-id-type="pmid">32245784</pub-id><pub-id pub-id-type="pmcid">PMC7164391</pub-id></element-citation></ref><ref id="CR129"><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zhang</surname><given-names>L</given-names></name><name name-style="western"><surname>Liu</surname><given-names>Y</given-names></name></person-group><article-title>Potential interventions for novel coronavirus in China: a systematic review</article-title><source>J Med Virol</source><year>2020</year><volume>92</volume><fpage>479</fpage><lpage>490</lpage><pub-id pub-id-type="doi">10.1002/jmv.25707</pub-id><pub-id pub-id-type="pmid">32052466</pub-id><pub-id pub-id-type="pmcid">PMC7166986</pub-id></element-citation></ref><ref id="CR131"><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zhang</surname><given-names>Q</given-names></name><name name-style="western"><surname>Li</surname><given-names>Y</given-names></name><name name-style="western"><surname>Xu</surname><given-names>F</given-names></name><etal/></person-group><article-title>Optimization of submerged fermentation medium for matrine production by Aspergillus terreus, an endophytic fungus harboring seeds of Sophora flavescens, using response surface methodology</article-title><source>Mycobiology</source><year>2017</year><volume>45</volume><fpage>90</fpage><lpage>96</lpage><pub-id pub-id-type="doi">10.5941/MYCO.2017.45.2.90</pub-id><pub-id pub-id-type="pmid">28781541</pub-id><pub-id pub-id-type="pmcid">PMC5541153</pub-id></element-citation></ref><ref id="CR132"><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zhang</surname><given-names>Y-J</given-names></name><name name-style="western"><surname>Zeng</surname><given-names>G</given-names></name><name name-style="western"><surname>Pan</surname><given-names>H-X</given-names></name><etal/></person-group><article-title>Immunogenicity and safety of a SARS-CoV-2 inactivated vaccine in healthy adults aged 18&#8211;59 years: report of the randomized, double-blind, and placebo-controlled phase 2 clinical trial</article-title><source>Medrxiv</source><year>2020</year><volume>25</volume><fpage>1026</fpage></element-citation></ref></ref-list></back></article></pmc-articleset>